烏克蘭人醒來發現川普暫停援助,感到「被背叛」

(SeaPRwire) -   烏克蘭基輔——週二,烏克蘭人醒來,得知川普政府已暫停對其對抗俄羅斯入侵的軍事援助,此前幾天,一項消息加深了基輔與白宮之間的裂痕。 美國總統唐納·川普指示美國暫停對烏克蘭的所有援助,因為他尋求向烏克蘭總統弗拉基米爾·澤倫斯基施壓,要求他與俄羅斯進行和平談判。 該決定似乎暫停了在拜登政府領導下批准的武器交付,但尚不清楚已經在烏克蘭的武器系統的彈藥交付是否會受到影響。 “我感到被背叛,但由於某種原因,這種感覺並不是很強烈。我預料到川普方面會做出這樣的事情,”一位在俄羅斯庫爾斯克地區作戰的烏克蘭士兵說,烏克蘭於 2024 年 8 月在那裡發動了一場大膽的軍事入侵,以改善其談判地位。這位士兵不願透露姓名,以便自由地表達自己的想法,因為他沒有被授權向媒體發言。 其他人表示,此舉讓唐納·川普的意圖更加令人困惑。 烏克蘭議員兼外交事務委員會主席 Oleksandr Merezhko 說:“問題在於,不清楚川普想要什麼,以及他的行為目的是什麼。” “截至今天,他似乎越來越傾向於俄羅斯,並試圖迫使烏克蘭接受俄羅斯的要求。” 他告訴美聯社:“這看起來很糟糕——迫使較弱的一方接受較強侵略者的條款。” 自川普上任以來,基輔一直擔心對烏克蘭的援助可能被停止,而且近幾週,隨著川普的團隊與俄羅斯就烏克蘭戰爭展開雙邊會談,以及川普對澤倫斯基的態度變得越來越輕蔑,美烏關係出現了下滑。 俄羅斯國家 RIA Novosti 通訊社援引俄羅斯議會下院國防委員會主席、退役將軍 Andrei Kartapolov 的話預測,烏克蘭將在幾個月內耗盡其現有的彈藥儲備。“我們需要保持壓力,並繼續使用遠程精確武器打擊他們基地和倉庫,以摧毀庫存,”他說。 川普週一表示,他仍然有興趣簽署一項協議,將烏克蘭的部分礦產交給美國,澤倫斯基也表示他準備簽署該協議。 烏克蘭倡導組織 Razom for Ukraine 表示:“通過突然停止對烏克蘭的軍事援助,川普總統讓烏克蘭人自生自滅,並向俄羅斯發出了繼續向西推進的綠燈。” “Razom for Ukraine 敦促白宮立即扭轉局面,恢復軍事援助,並向普丁施壓,要求他結束其可怕的入侵。”本文由第三方廠商內容提供者提供。SeaPRwire (https://www.seaprwire.com/)對此不作任何保證或陳述。 分類: 頭條新聞,日常新聞 SeaPRwire為公司和機構提供全球新聞稿發佈,覆蓋超過6,500個媒體庫、86,000名編輯和記者,以及350萬以上終端桌面和手機App。SeaPRwire支持英、日、德、韓、法、俄、印尼、馬來、越南、中文等多種語言新聞稿發佈。

Nissin Foods (Hong Kong) Charity Fund Supporting Talents in Food and Nutritional Sciences for the Third Consecutive Year

HONG KONG, Mar 3, 2025 - (ACN Newswire via SeaPRwire.com) - Nissin Foods (Hong Kong) Charity Fund (“Charity Fund”) announced its continued support for outstanding food and nutritional sciences students from The Chinese University of Hong Kong (“CUHK”) for the third consecutive year. The 2024-2025 Nissin Foods Scholarship Presentation Ceremony was held today to present scholarships to 13 undergraduate and postgraduate students, who strive for excellence in their academic performance and aspire to become future industry leaders.Established by the Charity Fund and CUHK in 2022, the scholarship will cover their full tuition fees for the academic year, and is renewable, subject to annual performance review, with the intent to support the students throughout their study period, so that they can focus on their studies without worrying about financial burdens. The four new awardees for the 2024-2025 academic year are: LEUNG Hau Man, LO Chun Hei and WONG Siu Yu from CUHK’s Bachelor of Science in Food and Nutritional Sciences programme, and ZHOU Zhengming from the PhD programme. The nine renewed awardees are LAM Tsz Hang, SHUM Wai Hang, CHAN Hoi Yi, HSU Po Ling, KWAN Ka Yi, LAM Shuk Fan and WONG Wai Yee from the Bachelor’s degree programme, and ZHOU Dandan, LIN Yuhong from the PhD programme. Mr. Kiyotaka ANDO, Chairman of Nissin Foods (Hong Kong) Charity Fund, said, "At Nissin Foods, we believe that food-related jobs are sacred professions. They serve both life and society. We share the values with The Chinese University of Hong Kong in nurturing outstanding and caring food professionals, who will contribute to Hong Kong's development. By empowering students studying food and nutritional sciences in CUHK and elite athletes aspiring to become teachers from the Education University of Hong Kong, we promote a healthy lifestyle through food and sports. This reflects the vision of our founder, Mr. Momofuku Ando, who said, ‘Eating and sports are the two axles of health."Professor Anthony CHAN, Pro-Vice-Chancellor and Vice-President of The Chinese University of Hong Kong, expressed his genuine gratitude for the generous support of the Charity Fund to CUHK, said, "Mr. Momofuku Ando, the Founder of Nissin Foods, was a visionary leader who dedicated himself to serve our society through technological innovation and had the courage to create positive change in our lives. His spirit continues to inspire many of us. CUHK has all along been committed to providing fertile ground for nurturing the future leaders of our society. We feel privileged that our vision in advancing higher education has been shared by Nissin Foods."Ms. WONG Wai Yee, on behalf of all the scholarship recipients, thanked the Charity Fund and CUHK for setting up the scholarship scheme and presented a booklet of appreciation from the 13 awardees to Mr. Kiyotaka ANDO. She said, "This scholarship empowers us to pursue our passions and aspirations in the realm of food and nutrition without constraints. As Nissin Foods Scholars, we are driven by a spirit of innovation to contribute to solutions for a secure and healthy global food supply, ensuring that the benefits of food and nutrition reach every corner of the world."PhotoMr. Kiyotaka ANDO, Chairman of Nissin Foods (Hong Kong) Charity Fund (middle right), and Professor Anthony CHAN, Pro-Vice-Chancellor and Vice-President of CUHK (middle left), attended the 2024-2025 Nissin Foods Scholarship Presentation Ceremony today. There are 13 scholarship recipients for the 2024-2025 academic year. The four new awardees this year are (front, from left to right) LEUNG Hau Man, LO Chun Hei and WONG Siu Yu from CUHK’s Bachelor of Science in Food and Nutritional Sciences programme, and ZHOU Zhengming from the PhD programme. The nine renewed awardees are: (back, from left to right) LAM Tsz Hang, SHUM Wai Hang, ZHOU Dandan, CHAN Hoi Yi, HSU Po Ling, KWAN Ka Yi, LAM Shuk Fan and WONG Wai Yee, and LIN Yuhong from the Bachelor’s degree or the PhD programme.About Nissin Foods (Hong Kong) Charity FundThe Nissin Foods (Hong Kong) Charity Fund (“Charity Fund”) was set up in September 2020 by way of a trust deed by Nissin Foods Company Limited (Stock code: 1475). The objectives of the Charity Fund are: a) to advance education, teaching, learning, arts, science and academic research; b) to make provision for people in need; and c) to carry out works of a charitable nature that are beneficial to the Hong Kong community.   Copyright 2025 ACN Newswire via SeaPRwire.com.

Hong Kong International Jewellery Show opens today showcasing global innovative designs

- The Hong Kong International Jewellery Show launches today (4 March) and runs until 8 March, showcasing a wide range of designs incorporating creative and cultural elements- The debut “Young Jewellery Designer Arena” showcases the creativity and craftsmanship of up-and-coming talents- The results of two major jewellery design competitions are revealed today. The International Jewellery Design Excellence Award features 80 worldwide award-winning pieces competing for the "Champion of the Champions". The design that clinched both the Best of Show Award in the Open Group and the Craftsmanship & Technology Award in the Hong Kong Jewellery Design Competition was a beautifully crafted ring inspired by Monet's "Water Lilies"HONG KONG, Mar 4, 2025 - (ACN Newswire via SeaPRwire.com) - The 41st Hong Kong International Jewellery Show, organised by the Hong Kong Trade Development Council (HKTDC), opens today at the Hong Kong Convention and Exhibition Centre (HKCEC) and runs for five consecutive days, closing on 8 March. It runs concurrently with the 11th Hong Kong International Diamond, Gem & Pearl Show which opened on Sunday (2 March) at AsiaWorld-Expo and finishes on 6 March. This year's twin jewellery shows have attracted some 4,000 exhibitors from more than 40 countries and regions, showcasing a spectrum of jewellery raw materials, finished products and technological tools, helping to create an international one-stop jewellery trading platform.Leading the trend with innovative and fashionable designsThe jewellery industry is increasingly focusing on fashionable styles, with innovative designs becoming key to helping products stand out in the market. For many years, the Hong Kong International Jewellery Show has provided an excellent platform for exhibitors to showcase their boundless creativity and exquisite craftsmanship. This year, Hong Kong exhibitor OSI Vitoria Jewelry (Booth: CEC GH-E08) introduces a floral necklace featuring a 62-carat emerald surrounded by more than 3,400 spinels, sapphires and diamonds, depicting the dazzling moment of fireworks lighting up the sky. Japanese exhibitor Jewelry of Raden & Urushi (Booth: CEC 1CON-016) presents a dragon-shaped brooch and pendant made of 18K gold, Akoya pearls, diamonds and mother-of-pearl, with intricate craftsmanship that imbues the design with life. Australian exhibitor Autore Pearls Pty Ltd (Booth: CEC GH-C32) showcases a vivid snake-shaped necklace that echoes the Year of the Snake, adorned with pearls, diamonds and gemstones. In the newly added Gold Jewellery Zone, Malaysian exhibitor Chl Innovation Industries Sdn Bhd (Booth: CEC 3E-D15) exhibits a durian pendant with distinctive local charm.Many exhibitors keep their fingers on the pulse of jewellery trends and launch creative products incorporated with traditional cultural elements. Hong Kong exhibitor Zuri Jewelry Company Limited (Booth: CEC 1E-C18) capitalised on Hong Kong’s “panda economy” to introduce its "Panda and Bamboo" jewellery collection. Changzhou Yi'an Jewelry Co., Ltd (Booth: CEC 1CON-029) from Mainland China harnesses filigree inlay technique, an almost-lost craft that is part of China’s intangible cultural heritage, to create 18K gold wheatears – a piece that won the Best Design Award in the 2019 Tiangong Awards.A new addition to this year’s show is the Young Jewellery Designer Arena, showcasing the creations and craftsmanship of up-and-coming talents to global buyers. The event also features 18 national, regional and industry pavilions, including the UK Pavilion led by British Jewellery & Giftware International with sophisticated jewellery pieces from eight British designers.Two major jewellery design competitions discover and nurture new talentsThe HKTDC has always put great emphasis on discovering and nurturing emerging talents to further elevate the standard of jewellery design. This year, it has once again joined hands with The Jewellers’ & Goldsmiths’ Association of Hong Kong Limited, Hong Kong Jewellery & Jade Manufacturers Association, Hong Kong Jewelry Manufacturers' Association and the Diamond Federation of Hong Kong, China Ltd to organise the 7th International Jewellery Design Excellence (IJDE) Award and the 26th Hong Kong Jewellery Design Competition (HKJDC) to identify new talents. The award ceremonies for the two competitions were held this morning and the winning entries will be on display at the Hall 1D and 1E Concourse throughout the International Jewellery Show.  Held for the first time since the pandemic, the 2025 IJDE Award received an enthusiastic response with 80 award-winning entries from nine countries and regions competing for the highest honour – the “Champion of the Champions”. The entries were assessed by an esteemed panel of judges with Lawrence Ma, Chairman of the HKTDC Hong Kong International Jewellery Show and HKTDC Hong Kong International Diamond, Gem & Pearl Show Fair Organising Committee, serving as chief judge and other members including representatives from L’ECOLE, School of Jewelry and the De Beers Group, among others. (See Table 1 for the list of selected winning entries from the 7th IJDE Award.)The theme for this year's HKJDC was "Lasting Brilliance", encouraging participants to showcase the enduring allure of jewellery through their creations. The competition was divided into an Open Group and Student Group and received a total of 86 entries. The judging panel, made up of six professionals from diverse fields such as jewellery and design, selected the winning entries after careful consideration. (See Table 2 for the list of selected winning entries from the 26th HKJDC.)Series of events enhance industry networkingA jewellery networking reception is being held tonight to boost connections among participants, welcoming jewellery industry representatives and both local and international buyers. Salina Yan, Permanent Secretary for Financial Services and the Treasury (Financial Services) of the Hong Kong SAR Government, will be the Guest of Honour. In addition, three jewellery parades will be held during the show, echoing its "Symphony of Sparkles" theme with displays of exquisite jewellery pieces. Over the course of the twin jewellery shows, more than 30 industry seminars, parades and other activities are being organised to further facilitate industry exchange.Table 1: Selected winning entries from the 7th International Jewellery Design Excellence AwardChampion of the ChampionsTitle of winning design: The KaleidoscopeDesigner: Nadia Neuman (Australia)Category: NecklaceDescription*:Designed with interchangeable components, this can be worn in a number of ways and features a fully functioning kaleidoscope. It showcases the beauty and versatility of natural coloured diamonds in both polished and rough formsInnovative and Uniqueness in Design AwardTitle of winning design: Summer Night CelebrationDesigner: Ying Chen CHEN (Taiwan)Category: EarringsDescription*:The inspiration for this piece comes from the mystical Barringtonia flower – a night fairy of the summer. Her life lasts only for a single nightAs dusk falls, she blooms in quiet elegance, only to gently descend with the first light of dawn. Though her existence is fleeting, she shines like fireworks and is breathtakingly beautifulIn this design, I sought to capture the moment when the stamens burst forth from the bud, with countless filaments unfurling like delicate tendrils, radiating boundless energy, vitality and freedom. This imagery deeply moved me, reminding me that “Life, like a flower, is fleeting – not measured by its length, but by whether it has burned brightly”As a jewellery designer, I often ask myself: what can I leave behind in this world' Perhaps, through my creations, I can transform those fleeting moments of emotion into eternal beautyCraftsmanship AwardTitle of winning design: Born of BlueDesigner: CHAN Hoi Yi (Hong Kong)Category: Pendant/BroochDescription*:Inspired by a proverb from my favorite philosopher Xunzi: "Born of blue, but better than blue"Blue dye was distilled from the indigo plant, but the dye was bluer than the plant itself. The knowledge taught by teacher made the students surpass the teacher himselfThis inspired my design like a visual metaphor: the Chinese-Cloud symbolises knowledge (an everchanging form/law of nature)ï¼›Chinese-Knots symbolise teacher/students (from a simple to a complex shape, to the deepening of blue colours. The progress symbolises self-improvement)I admire the vague elegance in this proverb. It's humble, pure, not flashy, with a scent of scholarly temperament, with goodwill and charm. It may sound a bit naive and idealistic today, but that’s what I want to express in this jewelleryAesthetics AwardTitle of winning design: ContemplationDesigner: Mariia EFIMOVA (Russia)Category: RingDescription*:In a world where everything happens too fast, beauty is commonplace, and we are often seduced only by the outside. But the underside sometimes says much more. "Contemplation" is an invitation to stop and a reminder that true beauty lies within us Table 2: Selected winning entries from the 26th Hong Kong Jewellery Design CompetitionOpen Group – Best of Show Award and Craftsmanship & Technology AwardTitle of design: Romance & ClassicsDesigner: Tse Ka-wingCategory: RingDescription*:Jewellery and renowned artworks share an inseparable relationship and common origins. The designer drew inspiration from elements of Impressionist painter Claude Monet's "Water Lilies", using jewellery to showcase the romance and elegance of classic paintingsOpen Group – Best of Show AwardTitle of design: Victoria • ButterflyDesigner: Chan Wing-longCategory: RingDescription*:Against the backdrop of Victoria Harbour, a giant butterfly flies high in the air, blending colour and shadows. The butterfly is like a dream, conveying people's longing and desire for the future. Each flap of the butterfly’s wings is a hymn to lifeOpen Group – Best of Show AwardTitle of design: WHIMSYDesigner: Chow Tin-yiCategory: Pendant/BroochDescription*:The hourglass cradles the gentle dreams of childhood, each glowing grain of sand falls softly to capture the delicate passage of time and its precious moments. A pendant, delicate and detachable, imbues the piece with elegance and personality, speaking of eternity and the sparkle of dreamsStudent Group – ChampionTitle of design: Blossom in PorcelainDesigner: Liu KanglanSchool: The Hong Kong Polytechnic UniversityCategory: RingDescription*:The blue and white porcelain is a manifestation not only of beauty, but also the passing of time and the continuity of Chinese culture. Incorporating a blue and white contrast and complex patterns into the design reflects the enduring appeal of traditional Chinese porcelain – a quality that shines stillStudent Group – 1st Runner-upTitle of design: Divine WhispersDesigner: Mak Wing-muiSchool: Saint Francis UniversityCategory: EarringsDescription*:The earrings draw inspiration from the sanctity of cathedrals, featuring geometric lines that outline the elegant silhouette of spires and domes. The cross atop symbolises eternal blessings and protection, while the central purple gemstone resembles heavenly light shining down. Adorned with vibrant enamel, the earrings reflect the dazzling brilliance of stained glass under sunlightStudent Group – 2nd Runner-upTitle of design: OliviaDesigner: Lau Cheuk-laiSchool: HKCT Institute of Higher EducationCategory: Bracelet/NecklaceDescription*:Olivia, a name inspired by the enduring legacy of the olive, embodies timeless elegance. The necklace, meticulously handcrafted with bold but lightweight meshed, hollowed constructions, features a 4-carat cushion-cut ruby that, like the olive, symbolises longevity and resilienceBeyond its luxurious appeal, Olivia represents family heritage and timelessness, akin to the olive tree’s historical significance, with over 6,000 years of cultural influence in the Mediterranean. Capturing enduring brilliance and embodying timeless virtues and beliefs, makes this a legacy piece for generations *The designers provided the description for their award-winning workFull list of the winning entries from the 7th International Jewellery Design Excellence Award: https://hkjewellery.hktdc.com/pdf/2025/IJDEA2025.pdfFull list of the winning entries from the 26th Hong Kong Jewellery Design Competition: https://www.hktdc.com/event/hkjewellery/en/the-26th-hong-kong-jewellery-design-competition-result-announcementThe 41st Hong Kong International Jewellery Show, organised by the HKTDC, commenced today at the Hong Kong Convention and Exhibition Centre, running in parallel with the 11th Hong Kong International Diamond, Gem & Pearl Show at AsiaWorld-Expo. The twin shows have attracted the participation of some 4,000 exhibitors from more than 40 countries and regionsHong Kong exhibitor OSI Vitoria Jewelry (Booth: CEC GH-E08) in the Hall of Extraordinary introduces a floral necklace featuring a 62-carat emerald surrounded by more than 3,400 gems and diamonds, depicting the dazzling moment of fireworks lighting up the skyIn the Designer Jewellery Galleria, Japanese exhibitor Jewelry of Raden & Urushi (Booth: CEC 1CON-016) presents a dragon-shaped brooch and pendant made of 18K gold, Akoya pearls, diamonds and mother-of-pearlAustralian exhibitor Autore Pearls Pty Ltd (Booth: CEC GH-C32) showcases a snake-shaped necklace that echoes the Year of the Snake, adorned with pearls, diamonds, and gemstonesThe Young Jewellery Designer Arena debuts at this year's International Jewellery Show, showcasing the creations and craftsmanship of up-and-coming designers to global buyersWinners of the 7th International Jewellery Design Excellence Award pictured at the award ceremony with distinguished guestsWinners of the 26th Hong Kong Jewellery Design Competition pictured at the award ceremony with distinguished guestsPhoto download: https://bit.ly/3QI66F3Fair detailsHong Kong International Jewellery ShowDateOpening hours4 March 2025 (Tuesday)10:30am-6:30pm5-7 March 2025 (Wednesday to Friday)10am-6:30pm8 March 2025 (Saturday)10am-5:30pmVenueHong Kong Convention and Exhibition Centre, 1 Expo Drive, Wan ChaiPress Registration & Media CentreMedia representatives can register at the entrance of HKCEC Hall 1D Concourse, or at the HKTDC Media Centre (G/F, Expo Drive Entrance, HKCEC) by presenting a business card or media identification.Hong Kong International Diamond, Gem & Pearl ShowDateOpening hours2 March 2025 (Sunday)10:30am-6:30pm3 -5 March 2025 (Monday to Wednesday)10am-6:30pm6 March 2025 (Thursday)10am-5:30pmVenueAsiaWorld-Expo, Hong Kong International Airport, Lantau, Hong KongPress registration and Media CentreMedia representatives can register at the entrance of AsiaWorld-Expo’s East Lobby (Opposite Hall 3 next to the escalator), or at the Media Centre (Room 201C, 2/F) by presenting a business card or media identification. ****For security reasons, all media will be required to present a name card and valid photo-bearing identity card (or passport) for press registration. Individuals with a valid press pass will be required to present their identity card (or passport) again at the entrance to the exhibition halls. Please allow sufficient time for registration.Websites Hong Kong International Jewellery ShowHong Kong International Diamond, Gem& Pearl ShowWebsitehttps://www.hktdc.com/event/hkjewellery/enhttps://www.hktdc.com/event/hkdgp/enSelected productshttps://bit.ly/4hE1ifzShuttle bus arrangementhttps://www.hktdc.com/event/hkjewellery/en/travel-to-fairground-hkcechttps://www.hktdc.com/event/hkdgp/en/travel-to-fairground-aweActivity listhttps://www.hktdc.com/event/hkjewellery/en/intelligence-hubhttps://www.hktdc.com/event/hkdgp/en/intelligence-hubHKTDC Media Room: https://mediaroom.hktdc.com/enMedia enquiriesPlease contact HKTDC’s Communication & Public Affairs Department:Sharon HaTel: (852) 2584 4575Email: sharon.mt.ha@hktdc.orgSerena CheungTel: (852) 2584 4272Email: serena.hm.cheung@hktdc.orgClayton LauwTel: (852) 2584 4472Email: clayton.y.lawuw@hktdc.orgAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus.  Copyright 2025 ACN Newswire via SeaPRwire.com.

Hua Medicine Awarded Shanghai Innovative Enterprise Headquarters

SHANGHAI, Mar 3, 2025 - (ACN Newswire via SeaPRwire.com) - On February 27th, the awarding ceremony of the second batch of Shanghai Innovative Enterprise Headquarters was held in Shanghai. Gong Zheng, Deputy Secretary of Shanghai Municipal Party Committee and Mayor of Shanghai, awarded the certificates to 49 innovative enterprise headquarters, and Hua Medicine was among them. Dr. Li Chen, the founder and CEO of the Company, went on stage to receive the award and delivered a speech as a representative of the enterprises.(Gong Zheng, Deputy Secretary of Shanghai Municipal Party Committee andMayor of Shanghai, awarded the titles to innovative enterprise headquarters)Innovative enterprises are an important part of Shanghai's modern industrial system and the source of vitality for Shanghai's high-quality development. In recent years, innovative enterprises in Shanghai have been growing and developing rapidly, having an obvious driving effect on the industry. The enterprises awarded this time are from key industrial fields such as integrated circuits, biomedicine, artificial intelligence, digital economy, and emerging strategic comprehensive industries. All the selected enterprises exhibit the characteristics of strong innovation leadership, vigorous development vitality, and obvious agglomeration development. (Certificate of innovative enterprise headquarters)Hua Medicine, headquartered in Shanghai but with a global outlook, is leveraging China's evolving pharmaceutical regulatory landscape and the innovative drug full-chain industrial environment such as the pharmaceutical research and development, production, and business environment created by Shanghai to continuously accelerate the transformation and implementation of innovative achievements. Hua Medicine took ten years to develop a globally first-in-class and national Class I new drug, glucokinase activator (GKA) dorzagliatin (Trade name:) independently, which was first launched in China, with a globally new target and a new mechanism.In September 2022, dorzagliatin was approved for marketing by the National Medical Products Administration of China for the treatment of type 2 diabetes. It is the first GKA approved for marketing worldwide and has also become the tenth class of diabetes treatment drugs recognized by the World Health Organization (WHO). By the end of 2023, dorzagliatin was successfully included in China's National Reimbursement Drug List (NRDL), greatly improving the accessibility and affordability of this innovative drug for patients.As a global innovation leader in the GKA field, Hua Medicine has received national-level awards on multiple occasions during the research and development period and after the product launch, and has undertaken major national projects. These include being consecutively selected as a major new drug development special project under the "12th Five-Year Plan" and the "13th Five-Year Plan” by the Ministry of Science and Technology, and winning the First Prize of the Science and Technology Award of the Chinese Pharmaceutical Association, among others. Currently, Hua Medicine is actively carrying out the development of the second-generation GKA and fixed combination preparations, aiming to bring more innovative and good drugs to patients in China and even globally in the fields of diabetes and its complications, such as obesity and diabetic nephropathy. (Dr. Li Chen delivered a speech as a representative of the enterprises)As a representative of the enterprises, Dr. Li Chen said in his speech at the awarding ceremony: "Coinciding with the new era and new journey of Shanghai accelerating the construction of a scientific and technological innovation center and fully promoting the upgrading and development of strategic emerging industries, Hua Medicine being recognized as the Shanghai Innovative Enterprise Headquarters is an affirmation of the enterprise's past and also an encouragement and inspiration for the enterprise's future development. Hua Medicine will continue to leverage its advantages of conceptual innovation, technological innovation, and model innovation, keep making progress, and contribute to the construction of Shanghai's scientific and technological innovation center and the innovative development of the biomedicine industry."Receiving the title of "Shanghai Innovative Enterprise Headquarters" this time is not only an honor for Hua Medicine but also a responsibility and mission. In the future, taking this as an opportunity, Hua Medicine will continuously increase its innovation investment and the ability of achievement transformation, continuously enhance its international competitiveness, provide more high-quality innovative drugs and treatment solutions for patients, help Shanghai's biomedicine industry reach new heights, and promote the construction of the "Healthy China" strategy.About Hua MedicineHua Medicine (The “Company”) is an innovative drug development and commercialization company based in Shanghai, China, with companies in the United States and Hong Kong. Hua Medicine focuses on developing novel therapies for patients with unmet medical needs worldwide. Based on global resources, Hua Medicine teams up with global high-calibre people to develop breakthrough technologies and products, which contribute to innovation in diabetes care. Hua Medicine's cornerstone product HuaTangNing (dorzagliatin tablets), targets the glucose sensor glucokinase, restores glucose sensitivity in T2D patients, and stabilizes imbalances in blood glucose levels in patients. HuaTangNing was approved by the National Medical Products Administration (NMPA) of China on September 30th, 2022. It can be used alone or in combination with metformin for adult T2D patients. For patients with chronic kidney disease (CKD), no dose adjustment is required. It is an oral hypoglycemic drug that can be used for patients with Type 2 diabetes with renal function impairment.For more informationHua MedicineWebsite: www.huamedicine.comInvestorsE-mail: ir@huamedicine.comMediaEmail: pr@huamedicine.com Copyright 2025 ACN Newswire via SeaPRwire.com.

General Atomics Introduces Quadratix Software Enterprise

SAN DIEGO, CA, Mar 3, 2025 - (ACN Newswire via SeaPRwire.com) - General Atomics is reshaping its software enterprise for the future, merging efforts from across business lines into a single technology grid delivering all-domain response and information dominance.The new Quadratix enterprise will bond GA's large software workforce and extensive suite of systems under a unified umbrella, merging solutions for:Autonomy, artificial intelligence and machine learningAirborne intelligence, surveillance, and reconnaissanceLand-based advanced sensingSea-based threat detectionSpace-based missions and satellite operationsCyber exploitationUnified data fusion and visualizationThis new cross-functional collaboration is designed to promote interoperability across all GA product lines, providing streamlined options for customers hoping to capitalize on the breadth and depth of General Atomics' expertise.As one of the largest privately held defense companies in the world, General Atomics has been a disruptive force in aerospace and defense technology for decades, employing more than 1,000 software engineers, programmers and related experts. Our new Quadratix enterprise merges software efforts from across the company's various affiliate divisions, including Aeronautical Systems, Inc. (GA-ASI); Electromagnetic Systems Group (GA-EMS); Integrated Intelligence, Inc. (GA-III); and other General Atomics holdings.The move offers new options for both current and future GA customers. One example is the unmanned aircraft delivered by GA-ASI, with its industry-leading Predator® series of UAS and future-forward autonomous jets, which will benefit from increased collaboration on autonomy, AI and ML produced by other GA divisions."We've transcended a one-for-one software build and arrived at an integrated suite of software solutions for our aircraft and our customers," said GA-ASI CEO Linden Blue. "We're moving out fast to meet our users' toughest challenges by grouping these solutions together under the Quadratix umbrella."GA's transformational technologies continue to revolutionize how global military forces address complex challenges and respond to evolving threats. From data processing, exploitation, and dissemination to data fusion and real-time situational awareness, our vertically integrated software teams work closely with our hardware engineers to build versatile, flexible systems that mesh seamlessly behind the scenes."Quadratix integrates across our full catalog of subordinate systems to command, control, collect, catalog, and communicate information and intelligence to customers," said Blue. "Built from our existing integrated network of proven systems and subsystems, Quadratix is GA's end-to-end solution for providing information dominance."For information about Quadratix, go to https://quadratix.ga.com .About General AtomicsGeneral Atomics is a defense and diversified technologies company, founded in 1955 as a division of General Dynamics and acquired by the Blue family in 1986. GA and affiliated companies operate on five continents. GA and affiliates produce unmanned aircraft and airborne surveillance systems, satellite surveillance, electro-magnetic rail gun, high-power laser, hypervelocity projectile, and power conversion systems. GA is a leader in nuclear fusion research, next-generation nuclear fission and advanced materials technologies. The company occupies 8+ million square feet of engineering, laboratory and manufacturing facilities and comprises over 13,000 employees.Contact InformationGA-ASI Media Relationsasi-mediarelations@ga-asi.comSOURCE: General Atomics Aeronautical Systems, Inc. Copyright 2025 ACN Newswire via SeaPRwire.com.

HighTide Therapeutics Announces Publication of Phase 2 Study of Berberine Ursodeoxycholate for the Treatment of Type 2 Diabetes Mellitus in JAMA Network Open

– Data from the proof-of-concept study showed berberine ursodeoxycholate was generally well tolerated and had beneficial therapeutic effect in improving glycemic, hepatic and cardiometabolic parameters– The multifaceted effects demonstrated by berberine ursodeoxycholate support this new molecular entity as a unique oral treatment option for T2DM and its comorbidities– T2DM phase 3 data readout is expected to be announced in the first half of 2025ROCKVILLE, MD and SHENZHEN, Mar 4, 2025 - (ACN Newswire via SeaPRwire.com) – HighTide Therapeutics, Inc. (2511.HK), a clinical stage biopharmaceutical company specializing in the development of multifunctional multi-targeted therapies for chronic liver and metabolic diseases, today announced that data from the Phase 2 proof-of-concept study evaluating berberine ursodeoxycholate (HTD1801) for the treatment of type 2 diabetes mellitus (T2DM) was published online in JAMA Network Open. The publication reports results of the randomized, placebo-controlled 12-week study to assess efficacy, safety and tolerability of HTD1801 compared to placebo in patients with T2DM. The trial achieved its primary endpoint by demonstrating a statistically significant and superior reduction in HbA1c at week 12 with HTD1801 versus placebo. A majority of patients treated with HTD1801 achieved target HbA1c <7%. Further, results show therapeutic benefit of HTD1801 on LDL and total cholesterol, markers of liver injury and systemic inflammation. In this study, HTD1801 was well tolerated with no treatment-related serious adverse events observed. These findings are being confirmed in ongoing Phase 3 studies.“We are encouraged by the results of this Phase 2 study. The study provides evidence that HTD1801 can treat the core aspects of metabolic syndrome, with potential to provide a spectrum of therapeutic effects that appear to address comorbid conditions that exacerbate disease and worsen prognosis of patients with T2DM,” said Dr. Linong Ji, Professor of Medicine at Peking University, Director of Peking University Diabetes Center and Director of the Department of Endocrinology and Metabolism, Peking University People’s Hospital, in Beijing, China.“Based on these positive findings, we are continuing to advance the clinical development of HTD1801 in our ongoing Phase 3 T2DM program with topline results expected in the first half of this year,” said Dr. Liping Liu, CEO of HighTide Therapeutics.About JAMA Network Open JournalJAMA Network Open is an international, peer-reviewed, open access, general medical journal that publishes research on clinical care, innovation in health care, health policy, and global health across all health disciplines and countries for clinicians, investigators, and policy makers. JAMA Network Open is a member of the JAMA Network, a consortium of peer-reviewed, general medical and specialty publications.About Berberine Ursodeoxycholate (HTD1801)Berberine ursodeoxycholate (HTD1801) is an orally delivered, gut-liver anti-inflammatory metabolic modulator being developed for the treatment of metabolic and digestive diseases. HTD1801, an ionic salt of berberine and ursodeoxycholate, is a new molecular entity with unique dual mechanisms of action, including AMP kinase activation and NLRP3 inflammasome inhibition. These two key mechanistic pathways have been associated with improvements in glucose metabolism, insulin resistance, lipid metabolism, and hepatic inflammation, potentially providing a comprehensive treatment platform for the multifaceted nature of complex metabolic diseases such as T2DM.About HighTide TherapeuticsHighTide Therapeutics, Inc. (Stock Code: 2511.HK) is a globally integrated biopharmaceutical company focusing on the discovery and development of first-in-class multifunctional multi-targeted therapies with poly-indication potential across multiple metabolic and digestive diseases with significant unmet medical needs. The Company is currently developing several clinical assets and holding global intellectual property rights, advancing multiple mid-to-late-stage clinical trials including therapy for metabolic dysfunction-associated steatohepatitis (MASH), type 2 diabetes mellitus (T2DM), severe hypertriglyceridemia (SHTG) and primary sclerosing cholangitis (PSC). Berberine ursodeoxycholate (HTD1801), the Company’s lead drug candidate, received Fast Track designation from the United States Food and Drug Administration for both MASH and PSC and Orphan Drug designation for PSC. HTD1801 has been included in the National Major New Drug Innovation Program under the 13th Five-Year Plan for Major Technology Project in China.For more information, please visit www.hightidetx.com. Contact: pr@hightidetx.com Copyright 2025 ACN Newswire via SeaPRwire.com.

Giftify, Inc. Launches Sports Ticket & Merchandise Savings Platform as Fan Expenses Surge

CardCash Platform Provides Cost-Reduction Strategy for High-Demand Sports Tickets and Merchandise Ahead of 2025 Major League Baseball (MLB) SeasonPlatform Supports Savings on Popular Sports Retailers Including StubHub, Nike, Adidas, Under Armour, Dick's Sporting Goods, and FanaticsSchaumburg, Illinois, Mar 5, 2025 - (ACN Newswire via SeaPRwire.com) - Giftify, Inc. (NASDAQ:GIFT) (the "Company"), the owner and operator of CardCash.com and Restaurant.com, and a leader in the incentives and rewards industry, today announced the expansion of its CardCash.com platform into the high-margin sports retail sector, offering consumers smart saving solutions for sports fans to save on tickets, apparel and game-day essentials as part of the Company’s strategic growth initiative for 2025.With the 2025 MLB season getting underway, fans are facing rising costs for tickets, gear, and game-day essentials. The average cost of attending a baseball game has climbed to $152 for a family of four, with premium seats seeing increases as high as 38.8%. But CardCash.com, a leading secondary gift card exchange operated by Giftify, is stepping up to help fans save.By using discounted gift cards from StubHub, Nike, Adidas, Under Armour, Dick’s Sporting Goods, and Fanatics, families can cut costs on tickets, jerseys, and game-day snacks.For example, a family of four heading to a Yankees game this season, their tickets alone would cost over $300, but by paying with StubHub gift cards purchased at CardCash.com at an 11% discount, they save over $30. Grabbing team gear from MLB Shop? That's another 11% saved.Making Baseball More Affordable“With rising ticket prices, fans are looking for ways to save without missing out on their favorite teams,” said Carol Rosenblum, Marketing Manager at CardCash.com. “By using our discounted gift cards, baseball lovers can cut costs by 10-20%, whether they’re buying tickets, upgrading their game-day outfits, or picking up tailgating gear.”Spring Cleaning: Turn Unused Gift Cards into Game-Day CashThe CardCash.com platform offers a comprehensive solution for sports fans: not only can they purchase discounted gift cards to save on upcoming expenses, but they can also monetize unused gift cards by exchanging them for cash or store credit—creating a complete financial ecosystem for sports enthusiasts. Just as fans engage in spring cleaning around their homes, CardCash encourages them to clear out their wallets and drawers of forgotten gift cards and transform that untapped value into memorable sports experiences.“As MLB teams welcome fans back to stadiums across the nation, this is the perfect time for people to check their wallets, trade in unused gift cards, and put those funds toward experiences they’ll actually enjoy,” said Ketan Thakker, CEO of Giftify, Inc. “Why let old gift cards go to waste when they can help get you to the ballpark? This sports fan initiative represents a key component of our 2025 growth strategy to penetrate high-frequency consumer spending categories while building recurring engagement with our platform.”About Giftify, Inc.Giftify, Inc. is a pioneer in the incentive and rewards industry with a focus on retail, dining & entertainment experiences, as the owner and operator of leading digital platforms, CardCash.com and Restaurant.com. CardCash.com is a leading secondary gift card exchange platform, allowing consumers and retailers to realize value by buying and selling gift cards at various scales. Its Restaurant.com is the nation’s largest restaurant-focused digital deals brand. Restaurant.com and our Corporate Incentives division connect digital consumers, businesses and communities offering thousands of dining, retail and entertainment deals options nationwide at over 184,000 restaurants and retailers. Restaurant.com prides itself on offering the best deal, every meal. Our gift cards and restaurant certificates allow customers to save at thousands of restaurants across the country with just a few clicks.For more information, visit: www.giftifyinc.com and www.cardcash.com and https://www.restaurant.com.Forward-Looking StatementsPress Releases may include forward-looking statements. In particular, the words “believe,” “may,” “could,” “should,” “expect,” “anticipate,” “estimate,” “project," "propose," "plan," "intend," and similar conditional words and expressions are intended to identify forward-looking statements. Any statements made in this news release about an action, event or development, are forward-looking statements. Such statements are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of the company. Accordingly, you should not place undue reliance on these forward-looking statements. Although the company believes that the expectations reflected in the forward-looking statements are reasonable, it can give no assurance that its forward-looking statements will prove to be correct. Investors are cautioned that any forward-looking statements are not guarantees of future performance and actual results or developments may differ materially from those projected. The forward-looking statements in this press release are made as of the date hereof. The company takes no obligation to update or correct its own forward-looking statements, except as required by law or those prepared by third parties that are not paid by the company. Statements in this press release that are not historical fact may be deemed forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Although Giftify, Inc. believes the expectations reflected in any forward-looking statements are based on reasonable assumptions, Giftify, Inc. is unable to give any assurance that its expectations will be attained. Factors that could cause actual results to differ materially from expectations include the company’s ability identify a suitable business model for the corporation.Investors Contacts:IR@giftifyinc.com Copyright 2025 ACN Newswire via SeaPRwire.com.

The Tapping Tapir Expands gutC Prebiotic Range with New Mix Berry Flavour

KUALA LUMPUR, Mar 3, 2025 - (ACN Newswire via SeaPRwire.com) - The Tapping Tapir, Malaysia’s pioneering brand of naturally flavoured sparkling beverages, has introduced the latest addition to its gutC prebiotic drink range – Mix Berry. The new flavour was officially unveiled at the brand’s wellness-driven Valentine’s Day event at Pickle Nation, themed "Self-Love and Gut Love." This unique gathering blended fitness, mindfulness, and social connection, reinforcing the importance of gut health and self-care in daily life.The new gutC Mix Berry flavourSince its inception in 2013, The Tapping Tapir has been dedicated to crafting all-natural, additive-free beverages made from real fruit juices, spices, and herbs. The gutC range, designed to support digestive wellness, reflects the brand’s commitment to health-conscious innovation. Recognising that 70% of the immune system is linked to gut health, gutC offers a low-calorie, prebiotic-infused selection of refreshing drinks that seamlessly fit into modern lifestyles.The Peach and Grape gutC flavoursWith the launch of Mix Berry, gutC now features four unique flavours: Mix Berry, Peach, Grape, and Lychee – the latter being an exclusive offering at 7-Eleven outlets. Each variant is carefully formulated with prebiotics (Inulin & Apple Cider Vinegar) to support digestion, Vitamin C to strengthen the immune system, and less than 2g of sugar, keeping each can under 15 calories for a guilt-free, refreshing beverage experience.To mark the launch of Mix Berry, The Tapping Tapir hosted a special Valentine’s Day event at Pickle Nation, bringing together a diverse crowd of health enthusiasts, professional athletes, influencers, and brand partners for a day of self-care and gut health awareness. Attendees were treated to an array of immersive experiences that highlighted movement, mindfulness, and social connection.Participants took part in pickleball training sessions, where beginners were introduced to the fast-growing sport under expert guidance. Wellness expert Piyachai Teo led guided meditation and breathwork workshops, promoting relaxation and stress relief. The event also featured an invigorating ice bath recovery experience, showcasing the benefits of cold therapy for muscle recovery and mental clarity. Throughout the day, guests were invited to visit sampling stations, where they had the first taste of the new gutC Mix Berry, alongside other beverages from The Tapping Tapir.KOLs, celebrities, and Pickleball players at the gutC Mix Berry launch party, including Cik Manggis, Atita Haris, Intan Sarah, and Fad AnuarThe highlight of the event was a social pickleball tournament, which saw friendly competition among influencers, celebrities, and professional pickleball players. Among the notable attendees were Toi Sieu Ee, Malaysia’s No. 2-ranked pickleball player, alongside well-known personalities such as Cik Manggis, Mark O’Dea, Luqman Hafidz, and Intan Sarah. VIP guests from Diamond & Platinum, Christy Ng, and Pickle Fox were also present, adding to the vibrancy of the occasion.The competition concluded with participants vying for prizes in the Men’s Doubles and Mixed Doubles categories, with winners taking home RM500 cash prizes and a Six Zero Quartz Paddle, generously sponsored by Pickle Fox. Adding an element of glamour, Diamond & Platinum awarded a diamond necklace to the best-dressed guest, while two lucky winners received RM500 shopping vouchers.With the expanded gutC range, The Tapping Tapir continues to redefine healthy beverages in Malaysia. As a brand known for innovation and sustainability, it remains committed to sourcing high-quality natural ingredients from local farmers, minimising processing, and prioritising eco-friendly packaging. Widely available in premium retailers, cafés, and hotels, The Tapping Tapir is making it easier for consumers to embrace healthier, more responsible choices in their daily lives.For more information about gutC Mix Berry and upcoming events, visit www.thetappingtapir.com or follow The Tapping Tapir on its Facebook and Instagram pages.– End –About The Tapping Tapir:Founded in 2013, The Tapping Tapir is a proudly Malaysian brand specialising in all-natural sparkling sodas crafted from real fruit juices, herbs, and spices—free from artificial colours, flavours, or preservatives. Embracing the philosophy of “Refreshingly WILD,” the brand celebrates nature’s best ingredients to create bold, tropical flavours with a refreshing twist.Each beverage is enriched with Vitamin C and contains less than 5g of sugar, naturally sweetened with stevia leaf extract. Committed to quality and sustainability, The Tapping Tapir works closely with local farmers to source fresh ingredients while ensuring all products are Halal-certified.Headquartered in Seri Kembangan, Selangor, The Tapping Tapir’s beverages are available nationwide through leading retailers, wholesalers, and online platforms.For more information, visit www.thetappingtapir.com Copyright 2025 ACN Newswire via SeaPRwire.com.

Eisai: Update on the Co-Promotion of the Oral Antifungal Agent Nailin Capsules 100mg in Japan

TOKYO, Mar 5, 2025 - (JCN Newswire via SeaPRwire.com) - Sato Pharmaceutical Co., Ltd. and Eisai Co., Ltd. announced today that they will conclude their co-promotion based on the co-promotion agreement in Japan regarding the orally-administered antifungal agent NAILIN® Capsules 100 mg (generic name: fosravuconazole) which is manufactured and marketed by Sato Pharmaceutical, as of March 31, 2025. Sato Pharmaceutical and Eisai have concluded a new agreement, under which Eisai will carry out promotional activities for this drug and transfer operations to Sato Pharmaceutical during a transition period from April 1, 2025, to March 31, 2026.NAILIN® Capsules 100 mg have been marketed by Sato Pharmaceutical in Japan since July 2018, with a co-promotion agreement between both companies. However, following the conclusion of the co- promotion agreement and the signing of a new agreement, Sato Pharmaceutical will independently conduct promotions starting from April 2026, following a transition period. Additionally, inrelation to this matter, Sato Pharmaceutical will pay Eisai a lump sum.About fosravuconazoleFosravuconazole is a new oral antifungal component developed by Eisai. Fosravuconazole is a prodrug that improves thesolubility and bioavailability of ravuconazole, the main active ingredient. When administered to humans, it is rapidly converted toravuconazole. Ravuconazole demonstrates antifungal activity by inhibiting ergosterol biosynthesis, a membrane component of fungal cells.In Japan, Seren Pharmaceuticals Inc., which was granted exclusive development and commercialization of this drug by Eisai, has been advancing its development for onychomycosis with Sato Pharmaceutical. Sato Pharmaceutical obtained manufacturing and marketing approval in January 2018, and since July 2018, it has been marketed as Nailin Capsule 100mg.Sato Pharmaceutical and Eisai entered into a license agreement in July 2024, under which Sato Pharmaceutical will undertake the development and commercialization in Asia and Oceania* for fungal diseases.*10 ASEAN member states, Australia, New Zealand, South Korea, TaiwanMedia InquiriesEisai Co., Ltd.Public Relations Department TEL: +81 (0)3-3817-5120Sato Pharmaceutical Co., Ltd. Public Relations Department TEL: +81-(0)3-5412-7354  Copyright 2025 JCN Newswire via SeaPRwire.com.

GA-ASI 歡迎美國空軍對新型 CCA 的命名:YFQ-42A

聖地亞哥, 2025年3月4日 - (亞太商訊 via SeaPRwire.com) - 通用原子航空系統公司(GA-ASI)對美國空軍為其協同作戰飛機(Collaborative Combat Aircraft, CCA)授予的新編號表示歡迎:這款新型無人戰鬥機將被命名為 YFQ-42A。此次公告於週一發布,緊隨早前 2024 年美國空軍決定,由 GA-ASI 負責開發和製造 YFQ-42A 的決定之後。 "我們很自豪能獲得新的官方飛機編號,」GA-ASI 總裁 David R. Alexander 表示。 “YFQ-42A 延續了 GA-ASI 悠久而卓越的歷史,可追溯至 1990 年代 RQ-1 Predator® 的首次亮相,該機後來更名為 MQ-1 Predator。這款無人機開創了 MQ-9A Reaper®、MQ-20 Avenger®,以及我們最新的 MQ-9B SkyGuardian® 和 SeaGuardian®,還有眾多其他機型。”"這些飛機代表了一段無與倫比的歷史,展現了可靠、高性能的無人作戰平台,滿足了美國作戰人員的需求,並為空中力量的新時代指明了方向。”美國空軍將 YFQ-42A 選定為 GA-ASI 協同作戰飛機(CCA)原型機的任務設計系列(MDS),這標誌著新一代無人戰鬥機的誕生。YFQ-42A 在未來衝突中對於聯合部隊的空中優勢至關重要,它將利用自主作戰能力和有人-無人協同作戰模式,在爭奪制空權的複雜環境中戰勝敵方威脅。美國空軍正在開發自主協同作戰平台(Autonomous Collaborative Platforms),以保持其空中優勢。像 YFQ-42A 這樣的半自主飛機將提升作戰靈活性、降低成本並提高任務執行效率。作為一款靈活且經濟高效的作戰倍增器,YFQ-42A 將進一步增強空中優勢。它旨在與當前及下一代有人駕駛飛機無縫集成,擴展任務能力,確保持續的空中主導地位。簡而言之,YFQ-42A 以更低的成本和符合威脅環境的時間框架,為戰鬥機部隊提供可負擔的大規模戰力。YFQ-42A 的命名繼承了美國空軍先前對 GA-ASI 的 XQ-67A 遠程感測站(Off-Board Sensing Station)的命名決策。 XQ-67A 由空軍研究實驗室訂購,用於支援 CCA 策略實施所需概念的開發。在美國空軍的命名系統中,"X" 代表用於測試和實驗的飛機,"Y" 代表初步生產代表機型,通常用於正式專案立項前,"F" 代表戰鬥機,"Q" 表示無人機。當生產代表機型進入正式生產階段,"Y" 字母將從前綴中移除。GA-ASI 將在 2025 年 3 月 3 日至 5 日於空戰研討會(Air Warfare Symposium)期間,在 #1003 展位展示 YFQ-42A 的六分之一比例模型。關於通用原子公司(GA) 通用原子公司是一家國防與多元技術企業,GA及其附屬公司業務遍及五大洲。GA附屬公司生產無人機及空中、太空與海上監視系統、光學通信、數據分析、航空母艦彈射與潛艇系統。GA亦是核聚變研究、下一代核裂變及先進材料技術的領先企業。欲了解更多信息,請訪問 www.ga-asi.com 。Avenger、Grey Eagle、Lynx、Predator、Reaper、SeaGuardian 和 SkyGuardian 是 General Atomics Aeronautical Systems, Inc. 在美國和/或其他國家註冊的商標。聯絡資訊GA-ASI 媒體關係asi-mediarelations@ga-asi.com 來源: General Atomics Copyright 2025 亞太商訊 via SeaPRwire.com.

周大福人壽成為啟德體育園開幕禮唯一鑽石贊助商

香港, 2025年3月4日 - (亞太商訊 via SeaPRwire.com) - 周大福人壽以啟德體育園開幕禮唯一鑽石贊助商的身份,與客戶、人生規劃師、合作夥伴、員工及其家人,於主場館一同觀賞開幕禮盛事,見證歷史時刻。繼早前成為啟德體育園獨家創始保險合作夥伴後,周大福人壽再成為啟德體育園開幕禮的鑽石贊助商,盡顯公司的雄厚資源及財務實力,以及全力支持香港特區政府推動本地文化、體育及旅遊發展,開創體藝新價值的承諾。周大福人壽執行董事兼行政總裁葉文傑表示:「周大福人壽是啟德體育園獨家創始保險合作夥伴,很榮幸成為開幕禮的鑽石贊助商,為香港以及公司的發展創造歷史。與園方在不同方面的合作使我們能在香港這個最大型的綜合體育及娛樂新地標,為本地運動員及表演者帶來更多發揮潛能空間,引入國際盛事,並推廣運動普及化。藉此,我們將為客戶呈獻優質多元的體驗,實踐開創保險新價值的承諾。」周大福人壽執行董事兼副行政總裁徐志堅(右二)聯同公司管理層於周大福人壽的貴賓房一同見證歷史時刻。周大福人壽於開幕禮期間在主場館內多處當眼位置展示品牌。開幕禮期間,周大福人壽的品牌展示於主場館內多處當眼位置,令現場及電視觀眾印象深刻,並將品牌影響力延展至各個平台。公司早前亦宣佈冠名贊助飛越啟德「小劍神」培訓計劃,助力發掘新一代代表中國香港隊的劍撃精英運動員,培育世界冠軍。計劃將於三月內接受報名,有興趣的家長可透過登記成為「周大福人壽.生活圈」會員為學童報名參與。關於周大福人壽周大福人壽保險有限公司(「周大福人壽」)扎根香港40年,為周大福創建有限公司(香港股份代號:659)的全資附屬公司,也是香港最具規模的壽險公司之一。作為周大福企業成員,周大福人壽緊扣鄭氏家族(「周大福集團」或「集團」)多元業務體系的雄厚資源,致力為客戶及其摯愛家人於「生活、成長、健康、傳承」的人生旅程中,提供個人化的匠心規劃、終身保障及優質體驗。憑藉集團財務實力及環球投資佈局,周大福人壽矢志成為亞太區領先的保險公司,持續開創保險新價值。傳媒聯絡周大福人壽保險有限公司品牌發展及傳訊部劉慧筠 (Zoey Lau)+852 2591 8314zoey.lau@ctflife.com.hk   周大福人壽保險有限公司(於百慕達註冊成立之有限公司) Copyright 2025 亞太商訊 via SeaPRwire.com.

歷史性全球反詐騙峰會在倫敦召開,共同打擊日益猖獗的網路詐騙

倫敦, 2025年3月4日 - (亞太商訊 via SeaPRwire.com) - 在一場具有里程碑意義的盛會中,英國將主辦2025年全球反詐騙峰會(GASS London 2025),匯聚前所未有數量的政策制定者、行業領袖及網絡安全專家。本次峰會由英國內政部、 全球反詐騙聯盟(GASA)、 Cifas和Euroconsumers聯合舉辦,被視為迄今最重要的反詐騙會議,旨在推動全球合作,應對網絡詐騙的猖獗增長。去年,網絡詐騙給全球經濟造成了近1.03萬億美元的損失。揭示全球反詐騙戰略  峰會將以重量級嘉賓的主旨演講拉開序幕,其中包括尊敬的漢森勳爵(The Rt Hon Lord Hanson of Flint),他將介紹英國在反詐騙領域的舉措,並強調全球合作的重要性,以共同應對這一日益嚴峻的威脅。討論將圍繞加強國際合作、統一詐騙防範措施以及利用技術保護全球消費者展開。 首日的專題討論將聚焦全球協調行動的迫切需求。會議將深入探討詐騙對個人和社會造成的影響,分享國際詐騙防範經驗,並強調公私合作夥伴關係在推動反詐騙立法及行業最佳實踐中的重要作用。此次峰會的核心目標是促進跨境、跨行業的合作。 行業領袖引領技術創新 峰會還將匯聚科技巨頭和金融機構,共同探討如何利用人工智能等前沿技術高效打擊詐騙分子。行業領袖將重點討論全球信號交換平台(Global Signal Exchange)的建立,這一創新平台旨在加強跨境數據共享,以更精確地追蹤和預防詐騙行為。GASS London 2025 第二日聚焦解決方案 峰會的第二天將專注於以解決方案為導向的研討會和專題討論。專家們將介紹最新的詐騙檢測與防範技術,包括深度伪造(Deepfake)識別以及數字身份安全策略。互動討論將為與會者提供機會,交流經驗並制定可執行的全球消費者保護策略,例如全球反詐騙聯盟(GASA)提出的建議——每個國家應設立專門的國家級反詐騙中心。 活動議程及門票信息請訪問:[ https://www.gasa.org/gass-2025-london ]( https://www.gasa.org/gass-2025-london ) 本次峰會旨在推動與會的公共及私人機構達成承諾,並制定至2026年及更遠未來的國際合作路線圖。 GASS London 2025 是向全球反詐騙戰線所有利益相關方發出的行動號召。本次峰會提供了一个獨特的契機,讓各國領袖攜手合作,共同抵禦每年影響數百萬人的網絡威脅。 特邀演講嘉賓包括:• 阿德·倫森(Aad Lensen)、杰羅恩·尼森(Jeroen Niessen)、魯本·范·威爾(Ruben van Well)——荷蘭警方 • 安德烈·斯科羅博加托夫(Andrei Skorobogatov)——英國內政部 • 安吉莉克·米特(Angelique Miet)——歐盟委員會 • 本·唐納森(Ben Donaldson)——英國金融(UK Finance) • 伊麗莎白·卡特博士(Dr Elizabeth Carter)——倫敦金斯頓大學(Kingston University London) • 埃爾斯·布魯格曼(Els Bruggeman)——Euroconsumers • 海德維格·努伊恩斯(Hedwige Nuyens)——國際銀行聯合會(IBFed) • 亨麗埃特·邦格斯(Henriette Bongers)——FraudeHelpdesk.nl • 傑伊德·里士滿(Jayde Richmond)——澳大利亞國家反詐騙中心(Australian National Anti-Scam Centre) • 讓-雅克·薩赫爾(Jean-Jacques Sahel)——谷歌(Google) • 尤里·亞伯拉罕(Jorij Abraham)——全球反詐騙聯盟(GASA) • 凱特·格里芬(Kate Griffin)——阿斯彭研究所(Aspen Institute) • Kitboga——YouTube 反詐騙主播(Scambaiter) • 勞拉·坎卡拉(Laura Kankaala)——F-Secure • 露西亞·哈里斯(Lucia Harris)——Match Group • 卢克·雷诺兹(Luke Reynolds)——万事达(Mastercard) • 莱妮特·欧文斯(Lynette Owens)——趋势科技(Trend Micro) • 迈克·哈雷(Mike Haley)——Cifas • 娜塔莉·布莱克(Natalie Black)——英国通信管理局(OFCOM) • 纳撒尼尔·格莱彻(Nathaniel Gleicher)——Meta活動議程及門票信息請訪問:[ https://www.gasa.org/gass-2025-london ]( https://www.gasa.org/gass-2025-london )聯絡信息Sam Rogers市場營銷總監, 全球反詐騙聯盟sam.rogers@gasa.org+31 (0) 645 130 670Hayley Paterson新聞與公關經理, Cifashayley.paterson@cifas.org.uk相關視頻來源: Global Anti-Scam Alliance相關文件: Global State of Scams Report - 2024.pdfState of Scams in the United Kingdom Report - 2024.pdf Copyright 2025 亞太商訊 via SeaPRwire.com.

重磅發佈 – 君聖泰醫藥在JAMA Network Open發表熊去氧膽小檗鹼治療2型糖尿病的臨床2期研究數據 療效顯著 多重代謝獲益 市場前景廣闊

- 具有多重代謝獲益的獨特口服治療藥物,潛在市場前景廣闊:最新臨床2期研究結果顯示,熊去氧膽小檗堿(HTD1801)在耐受性良好基礎上,可顯著改善血糖、肝臟及心血管相關的代謝指標,支援該新分子實體有潛力成為治療2型糖尿病(T2DM)及其合併症的一種獨特口服治療藥物,市場前景廣闊。- 療效顯著,安全性良好,獲得權威專家推薦:12周隨機對照試驗結果顯示, HTD1801治療組HbA1c水平較安慰劑組顯著下降,且多數患者達到理想的血糖控制目標(<7%),耐受性良好。北京大學糖尿病中心主任紀立農教授認為HTD1801有希望治療T2DM患者的共患病和多種代謝異常,具有為T2DM患者提供綜合臨床獲益的潛力。- HTD1801治療T2DM的臨床3期試驗關鍵數據即將在今年上半年公佈,有望進入商業化流程,為君聖泰未來發展提供強勁動力。深圳, 2025年3月4日 - (亞太商訊 via SeaPRwire.com) - 中國深圳、美國馬里蘭州羅克維爾,君聖泰醫藥(股票代碼: 2511.HK),一家專注于開發多功能多靶點創新療法、解決代謝性疾病及慢性肝病未滿足臨床需求的醫藥公司,今日宣佈,熊去氧膽小檗堿(HTD1801)治療2型糖尿病(T2DM)的臨床2期研究結果在期刊JAMA Network Open發表。該論文報告了一項為期12周的隨機雙盲、安慰劑對照研究的結果,旨在評估HTD1801相較安慰劑在T2DM患者中的有效性、安全性和耐受性。該試驗達到了主要終點,在第12周時,HTD1801治療組相對於安慰劑組的HbA1c水平顯著下降。多數接受HTD1801治療的患者達到了HbA1c <7%的控制目標,進一步分析顯示,HTD1801顯著改善了LDL-c、總膽固醇、肝損傷及系統性炎症的指標。在本研究中,HTD1801的耐受性良好,未觀察到與治療相關的嚴重不良事件。目前正在開展的3期臨床試驗將進一步驗證這些結果。北京大學糖尿病中心主任、北京大學人民醫院內分泌代謝科主任紀立農教授表示:"這項2期臨床研究的結果使我們備受鼓舞。該研究證明了HTD1801有潛力解決代謝綜合征的核心問題,有希望治療T2DM患者的共患病和多種代謝異常,具有為T2DM病患者提供綜合臨床獲益的潛力。"君聖泰首席執行官劉利平博士表示:"我們基於這些積極臨床資料繼續推進HTD1801治療T2DM的3期臨床項目,預計將在今年上半年公佈臨床3期試驗的關鍵數據。"關於JAMA及JAMA Network Open期刊JAMA(The Journal of the American Medical Association)是由美國醫學會出版的同行評審醫學期刊,創刊於1883年,涵蓋生物醫學各個領域,包括臨床醫學、公共衛生、健康政策等。作為醫學界的權威期刊,JAMA與《柳葉刀》、《新英格蘭醫學雜誌》和《英國醫學雜誌》並列為醫學界的四大頂級期刊,致力於推動醫學科學進步,提升臨床實踐水平,對全球健康產生深遠影響。JAMA Network Open是美國醫學會旗下的國際性開放獲取期刊,面向臨床醫生、研究者及政策制定者,發佈有關醫療創新及全球健康等高質量內容,憑藉其全球化視野和開放獲取平臺,JAMA Network Open為研究者提供高水平學術平臺,促進了醫學領域的國際合作與學術交流。關於熊去氧膽小檗堿(HTD1801)熊去氧膽小檗堿(HTD1801)是一種靶向腸-肝系統的口服抗炎及代謝調節劑,正在開發用於治療代謝及消化系統疾病。HTD1801作為熊去氧膽酸和小檗堿形成的離子鹽,是一種具有獨特雙機制的新分子實體,通過激活AMPK及抑制NLRP3發揮其生物學活性。這兩種關鍵機制與改善葡萄糖代謝、胰島素抵抗、脂質代謝和肝臟炎症相關,為T2DM等複雜代謝性疾病的治療提供綜合性解決方案。關於君聖泰醫藥君聖泰醫藥(股票代碼:2511.HK)是一家全球一體化的新型生物技術公司,專注代謝性疾病領域的重大未滿足臨床需求。以"標本兼治、深求治癒"這一DeepCure理念為目標,立足源頭創新,開發First-in-Class的原創新藥,以期為全球患者提供基於中國智慧的,安全、有效、綜合獲益的解決方案。基於自主知識產權,公司已構建豐富產品管線,在全球推進多項中、後期臨床試驗,開發代謝相關脂肪性肝炎(MASH)、2型糖尿病(T2DM)、嚴重高甘油三酯血症(SHTG)和原發性硬化性膽管炎(PSC)等適應症。作為同類首創的多靶點新分子實體,熊去氧膽小檗堿(HTD1801)被美國FDA授予2項"快速通道資格認定"、1項"孤兒藥資格認定",並獲得國家"十三五•重大新藥創制"科技重大專項支持。欲知更多資訊,敬請訪問www.hightidetx.com垂詢pr@hightidetx.com Copyright 2025 亞太商訊 via SeaPRwire.com.

穆罕默德·本·扎耶德人工智慧大學(MBZUAI)推出首個同類本科人工智慧課程,協助未來AI領袖成長

阿聯酋阿布扎比, 2025年3月4日 - (亞太商訊 via SeaPRwire.com) - 穆罕默德·本·扎耶德人工智慧大學(MBZUAI)正在重塑人工智慧教育格局,推出其首個本科課程。不同於傳統的人工智慧課程設置,該人工智慧理學學士專案融合了核心AI專業知識、領導力、創業精神、行業經驗及實際影響力,旨在培養未來的人工智慧領袖。MBZUAI 的本科課程具有創新性和跨學科特點,將為學生提供人工智慧領域的堅實基礎,例如機器學習、自然語言處理、計算機視覺和機器人技術,並在商業、金融、工業設計、市場分析、管理和溝通等方面提供跨學科培訓。學生將受益於實踐導向的課程,培養創業思維,以引領人工智慧變革。其目標是培養具有遠見卓識的思想家和多才多藝的問題解決者,以引領全球人工智慧發展。 MBZUAI 董事會主席海克·哈利法·穆巴拉克閣下(His Excellency Khaldoon Khalifa Al Mubarak)表示:“這一本科課程將在實現我們領導層願景方面發揮變革性作用,確保阿聯酋繼續在人工智慧研究、應用和商業化方面保持領先,以推動創新、經濟增長和社會進步。它將為本土新一代人才提供深厚的技術專長,並幫助他們理解人工智慧的廣泛影響。通過這一舉措,我們將增強國家培養高技能人才的能力,使其推動人工智慧進步,不僅造福我國和本地區,也惠及全球。” 除了核心的人工智慧技術技能,MBZUAI 還致力於培養新一代的人工智慧創新者、開發者、管理者和戰略家。該綜合課程將賦予他們領導能力、金融和法律基礎知識,以及管理、溝通和批判性思維等關鍵人文技能,這些能力對推動人工智慧的未來發展和應用至關重要。MBZUAI 的全新本科課程採用共駕式教育模式,將人工智慧融入學生教育旅程的各個方面。人工智慧將在學生的學習體驗中發揮核心作用,提升批判性思維和問題解決能力,使學生在快速發展的人工智慧領域脫穎而出。 課程將涵蓋深度學習、生成式人工智慧和科學人工智慧等前沿主題,同時提供商業和創業培訓。學生還將探索人工智慧在醫療健康、可持續生活、3D 視覺和混合現實等領域的最新應用。他們將有機會與全球各個人工智慧領域的頂尖專家合作,並與最先進的大型語言模型開發團隊進行實踐,包括 MBZUAI 旗下的世界領先阿拉伯語 LLM——JAIS(全球最先進的阿拉伯語大模型),以及 K2(唯一超越主要私營企業模型、可復現的第三方 LLM),從而獲得無與倫比的實踐經驗。MBZUAI 校長兼大學教授 Eric Xing 強調了該校的前瞻性教育理念:“我們的本科課程將是首創之舉,它將人工智慧教育與創業、問題發現及產品旅程中的關鍵技能相結合。我們正在重塑人工智慧教育的定義,不僅培養工程師,還培養企業家、設計師、影響者、高管和具有遠見的創新者,使他們能夠在各個行業和各個階段推動人工智慧創新。” 跨學科培訓和實踐學習將成為該課程的基石。學生將在學習過程中涉獵人文學科、商業及博雅教育,超越傳統計算機科學和 STEM 學科的界限。此外,他們還將參與行業合作實習、企業實訓、導師指導,並與人工智慧研究和產業領域的頂尖機構建立合作關係。 Xing 教授補充道:“我們的學生不僅僅學習理論和編程。他們將在社會與人文、市場與經濟等方面獲得深刻理解,並積累實踐經驗和自信心,從而推動並引領人工智慧專案,無論是在成熟企業中,還是通過自主創業。我們致力於讓畢業生在人工智慧快速變化的環境中做好充分準備。” MBZUAI 的本科課程提供兩大專業方向:人工智慧理學學士(商業方向),專注於商業整合與創業;人工智慧理學學士(工程方向),專注於人工智慧模型的開發與部署,並涵蓋各行業的實際應用。 學生將受益於高端人工智慧運算資源、智慧教室、專屬孵化空間以及在學術和產業領域均享有盛譽的師資團隊。這項開創性的課程向本地和國際學生開放,旨在吸引最聰明、最有抱負的人才,使 MBZUAI 站在本科人工智慧教育的最前沿。 Xing 教授最後表示:“我們不僅僅是在教育學生,而是在塑造未來人工智慧產業的人才和社區。透過這個本科課程,MBZUAI 正在樹立人工智慧教育的新標準,確保我們的畢業生具備變革產業和推動全球進步的能力。”關於穆罕默德·本·扎耶德人工智慧大學(MBZUAI) 穆罕默德·本·扎耶德人工智慧大學(MBZUAI)是一所位於阿布扎比的研究型大學,也是全球首所專注於通過人工智慧推動科學進步的大學。該校致力於培養新一代人工智慧領袖,通過世界一流的教育和跨學科研究推動創新和人工智慧的實際應用。2025 年,MBZUAI 推出了首個本科課程——人工智慧理學學士(Bachelor of Science in AI),涵蓋商業和工程兩個專業方向。 欲了解更多信息,請訪問: www.mbzuai.ac.ae 。 申請入學,請訪問 mbzuai.ac.ae 或聯繫 admission@mbzuai.ac.ae 。媒體諮詢,請聯繫:Aya SakouryMBZUAI 通訊主管Amy RogersMBZUAI 高級通訊專家media@mbzuai.ac.aeRoger Field/Aya HassanWallis PRSOURCE: MBZUAI Copyright 2025 亞太商訊 via SeaPRwire.com.

香港國際珠寶展今日盛大開幕 匯聚環球創新設計

- 香港國際珠寶展即日起(3月4日)至3月8日舉行,展示一系列具創意及文化元素的設計- 珠寶展增設「新晉珠寶設計師」專區,展示年輕設計師的創意和工藝- 兩大珠寶設計比賽今日揭盅,「國際珠寶設計大獎」雲集80件各地冠軍級作品角逐「冠軍中之冠軍」;「香港珠寶設計比賽」公開組大獎作品兼奪工藝獎,以莫內《睡蓮》作靈感製作戒指香港, 2025年3月4日 - (亞太商訊 via SeaPRwire.com) - 由香港貿易發展局(香港貿發局)主辦的第41屆香港國際珠寶展,今日起一連五日(3月4至8日)在香港會議展覽中心舉行,而第11屆香港國際鑽石、寶石及珍珠展已率先於周日(3月2日)在亞洲國際博覽館揭幕,展期至3月6日。今年珠寶雙展吸引約4,000家,來自超過40個國家和地區的參展商參與,展示各式各樣的珠寶原材料、首飾成品和工具技術,締造一站式國際頂尖珠寶商貿平台。珠寶展創新時尚設計引領潮流珠寶製品越來越注重時尚款式,創新設計成為產品脫穎而出的關鍵。香港國際珠寶展多年來為參展商提供優質平台,展示他們的無限創意和精湛工藝。今屆珠寶展展商之一、來自香港的維多利亞珠寶(展位:CEC GH-E08)推出的「煙花套鏈」,以62卡祖母綠為主石打造,周圍環繞逾3,400顆尖晶石、藍寶石及鑽石等,重現煙花綻放多彩的時刻。日本展商Jewelry of Raden & Urushi(展位:CEC 1CON-016)帶來以18K 黃金、阿古屋珍珠、鑽石、珍珠母貝鑲嵌的龍造型胸針和吊墜,細緻的造工令造型栩栩如生。澳洲展商Autore Pearls Pty Ltd(展位:CEC GH-C32)展示迎合蛇年的蛇形項鏈,鑲有珍珠、鑽石和寶石,活靈活現。馬來西亞展商俊輝創新工業股份有限公司(展位:CEC 3E-D15)於新增設的「黃金首飾」展區(Gold Jewellery),展示別具地方特色的榴槤吊墜。不少展商亦緊貼潮流推出創意產品,在設計中融入傳統文化元素。香港展商金致珠寶有限公司(展位:CEC 1E-C18)響應熊貓經濟,推出「熊貓與竹」珠寶系列。中國內地常州壹安珠寶有限公司(展位:CEC 1CON-029)利用幾近失傳的國家級非物質文化遺產「花絲鑲嵌工藝」,打造18K金飾麥穗,該作品曾在2019年設計天工獎中獲最佳設計獎。今年珠寶展更增設「新晉珠寶設計師」專區(Young Jewellery Designer Arena),向全球買家展示年輕設計師的創作與技藝。展會同時設有18個來自不同國家、地區及行業的展館,其中由British Jewellery & Giftware International牽頭的英國館,帶來八位當地設計師的珠寶首飾,別具特色。兩大珠寶設計比賽發掘及培育行業新星香港貿發局一向重視發掘及培育新生代為業界注入動力,進一步提升珠寶設計水平和品質。今年貿發局再與香港珠寶首飾業商會、香港珠寶玉石廠商會、香港珠寶製造業廠商會及香港鑽石總會合辦「第七屆國際珠寶設計大獎」及「第二十六屆香港珠寶設計比賽」,兩大比賽的頒獎典禮在今日上午舉行,各優勝作品會於珠寶展展覽廳1D及1E大堂展出。其中國際珠寶設計大獎是疫情後首次復辦,反應非常熱烈,接獲80件來自九個國家和地區的冠軍級作品,角逐「冠軍中之冠軍」等殊榮。比賽的評判團極具份量,除了邀得展會籌備委員會主席馬墉宜任首席評判,成員還包括L'ÉCOLE珠寶藝術學院、戴比爾斯集團(De Beers Group)等珠寶和設計業代表。(表一為第七屆國際珠寶設計大獎得獎作品)而今屆香港珠寶設計比賽的主題為「光華不息」,鼓勵參賽者透過設計展現珠寶持久的魅力。比賽分為公開組及學生組,共收到86份參賽作品,並由六名來自珠寶、設計等不同界別的專業評審,嚴選得獎作品。(表二為第二十六屆香港珠寶設計比賽得獎作品)一系列活動深化業界交流為增進業界聯繫,今日晚上舉行珠寶交流酒會接待海內外的珠寶業界、買家等代表,並由財經事務及庫務局常任秘書長(財經事務)甄美薇擔任主禮嘉賓。珠寶展更有三場珠寶匯演,呼應珠寶雙展「譜奏閃爍樂章」的主題,展示精選珠寶及首飾,體現創造之美。珠寶雙展期間將舉行超過30 場珠寶行業講座、匯演等活動,進一步推動行業交流。表一:第七屆國際珠寶設計大獎部分得獎作品冠軍中之冠軍得獎設計名稱︰The Kaleidoscope設計師︰Nadia Neuman(澳洲)類別︰項鍊作品描述:作品採用可互換組件的設計,有多種佩戴方式,並具有功能齊全的萬花筒。它展示了天然彩色鑽石在拋光和原始形式下的美麗和多功能性。最佳創意獎得獎設計名稱︰Summer Night Celebration設計師︰Ying Chen CHEN (台灣)類別︰耳環作品描述*:這件作品的靈感來自神秘的玉蕊花-夏日的仙子。她的生命僅持續一夜。黃昏降臨,她優雅、安靜地綻放,只為伴隨黎明的第一道曙光輕輕落下。雖然她的存在轉瞬即逝,但卻如煙火般閃耀,美麗得令人窒息。在設計中,我試圖捕捉花蕊從花蕾中綻放的瞬間,無數的花絲像纖細的捲鬚般舒展,散發出無限的能量、活力和自由。這幅意象深深打動了我,讓我想起「生命就像一朵花,轉瞬即逝-不是以它的花期長短來衡量,而是在乎它是否燦爛盛放。」身為珠寶設計師,我常常問自己「我能在這個世界上留下什麼?或許,透過我的創作,我可以把那些轉瞬即逝的情感轉化為永恆的美麗。」最佳工藝獎得獎設計名稱︰Born of Blue設計師︰Chan Hoi Yi(香港)類別︰吊墜/胸針作品描述*:作品受到我最喜歡的哲學家荀子的名言啟發:「青出於藍而勝於藍」。從靛藍植物中提取的藍色染料,顏色比植物本身更深;老師傳授學生知識,而學生在不斷學習中超越老師。它像一個視覺隱喻一樣啟發了我的設計:中國的祥雲圖案象徵知識(不斷變化的形式/自然法則); 中國結象徵老師/學生(從簡單到複雜的形狀,從淺藍色到深藍色,過程象徵著自我提升)。我欣賞這句名言中隱約的優雅。它謙遜、純粹、不浮華,帶著一股書生氣質,帶著善意與魅力。現在聽起來可能有些幼稚和理想化,但這正是我想從這件珠寶中表達的。最佳整體美感獎得獎設計名稱︰Contemplation設計師︰Mariia EFIMOVA (俄羅斯)類別︰戒指作品描述*:在這個一切都發生得太快的世界裡,美麗已是司空見慣。我們經常被外在所誘惑。但內在有時傳遞的信息更為豐富。「Contemplation」邀請大家停下來,提醒大家真正的美麗存在於內心中。表二:第二十六屆香港珠寶設計比賽部分得獎作品公開組大獎兼工藝技術獎作品名稱︰浪漫與經典設計師︰謝嘉榮類別︰戒指作品描述*:珠寶與名畫的關係密不可分,有著相同的淵源,設計師汲取了印象派畫家莫內作品《睡蓮》的元素,運用珠寶藝術完美展現經典名畫的浪漫與典雅。公開組大獎作品名稱︰維多利亞-蝶光設計師︰陳詠朗類別︰戒指作品描述*:在維多利亞港的景色中,化為一隻巨蝶,展翅高飛,閃爍著五光十色的光影。幻蝶如夢,傳遞人們對未來的憧憬與渴望。每次翅膀扇動,都是對生命的讚歌。最後,幻蝶化了光境,吸引世人駐足凝望,心隨之飛翔,共同編織那份對美好的追尋。成為夢的起點,綻放無盡可能。公開組大獎作品名稱︰童趣設計師︰周天怡類別︰吊墜/胸針作品描述*:沙漏承載童年的夢,每一粒夜光沙如星塵滑落,捕捉時間的流逝與珍貴,將希望與光芒封存其中。吊墜可拆卸的設計,賦予自由更換彩沙或香氛沙的可能,增添珠寶獨特魅力與個性。在流動的光影間,見證永恆與夢想的閃耀。學生組冠軍作品名稱︰藍韻花語設計師︰劉康藍就讀學校︰香港理工大學類別︰戒指作品描述*:藍色白花青的青花瓷不僅是一種美的體現,更是時間的沈澱和中華文化的延續。將其藍白相映和紋飾繁複的特點融入珠寶設計中,表達了青花瓷恆久的吸引力和隨著時間流逝依然閃耀的特質。學生組亞軍作品名稱︰聖華設計師︰麥泳梅就讀學校︰聖方濟各大學類別︰耳環作品描述*:耳環靈感源自教堂的神聖,造型勾勒出尖塔穹頂的典雅輪廓。穹頂上的十字架象徵著永恆的祝福,中央垂掛的紫色寶石猶如聖光在人間綻放,搭配色彩斑斕的琺瑯,就像教堂彩繪玻璃在陽光下的璀璨光華。每片琺瑯都象徵著信仰的力量,散發出持久而迷人的色彩。學生組季軍作品名稱︰紅鹽設計師︰劉卓禮就讀學校︰港專學院類別︰手鍊/項鍊作品描述*:作品名取自蘇軾《橄欖》的「紛紛青子落紅鹽」,當中的紅鹽有成熟橄欖之意。紅鹽落下後便不再使用樹的養分,果中的種子重新發芽生長。橄欖樹四季長青,開花結果,周而復始,光華不息,宛如代代相傳的家族瑰寶。*資料由得獎者提供「第七屆國際珠寶設計大獎」完整得獎名單:https://hkjewellery.hktdc.com/pdf/2025/IJDEA2025.pdf「第二十六屆香港珠寶設計比賽」完整得獎名單:https://www.hktdc.com/event/hkjewellery/tc/the-26th-hong-kong-jewellery-design-competition-result-announcement由香港貿易發展局主辦的第41屆香港國際珠寶展今日於灣仔會展隆重開幕,連同於亞博館舉行的第11屆香港國際鑽石、寶石及珍珠展,共匯聚來自全球超過40個國家及地區,約4,000家參展商。珠寶精粹廊展區內的維多利亞珠寶(展位:CEC GH-E08)以62卡祖母綠和逾3400顆寶石、鑽石等打造的「煙花套鏈」,重現煙花綻放多彩的時刻。日本展商Jewelry of Raden & Urushi(展位:CEC 1CON-016)在珠寶設計精選展區,帶來以18K 黃金、阿古屋珍珠、鑽石、珍珠母貝鑲嵌的龍造型胸針和吊墜。澳洲展商Autore Pearls Pty Ltd(展位:CEC GH-C32)展示的蛇形項鏈,鑲有珍珠、鑽石和寶石,活靈活現。今年珠寶展增設新晉珠寶設計師專區,為年輕設計師提供展示才華的平台。「第七屆國際珠寶設計大獎」一眾得獎者與嘉賓合照。「第二十六屆香港珠寶設計比賽」一眾得獎者與嘉賓合照。圖片下載︰https://bit.ly/3QI66F3展會資料:香港國際珠寶展展覽日期開放時間2025年3月4日(星期二)上午10時30分至下午6時30分2025年3月5日至7日(星期三至五)上午10時至下午6時30分2025年3月8日(星期六)上午10時至下午5時30分展覽地點灣仔博覽道1號香港會議展覽中心記者登記處及新聞中心新聞界代表請攜同名片及記者證到香港會議展覽中心展覽廳1D大堂,或到香港貿發局新聞中心(香港會議展覽中心博覽道入口──新翼地下)登記**香港國際鑽石、寶石及珍珠展展覽日期開放時間2025年3月2 (星期日)上午10時30分至下午6時30分2025年3月3至5日 (星期一至三)上午10時至下午6時30分2025年3月6日 (星期四)上午10時至下午5時30分展覽地點香港大嶼山香港國際機場亞洲國際博覽館記者登記處及新聞中心新聞界代表請攜同名片及記者證到亞洲國際博覽館東大堂入口(3號展館對面電梯旁),或到新聞中心(2樓201C會議室)登記****基於保安理由,記者須出示工作證及身份證或護照登記,方能辦理記者證,持大會發出記者證入場前,保安人員亦會要求出示身份證明文件,以確認身份。請預留足夠時間辦理記者證及入場。相關網頁 香港國際珠寶展香港國際鑽石、寶石及珍珠展展覽網頁http://hkjewelleryshow.hktdc.com/tchttp://hkdgp.hktdc.com/tc精選產品https://bit.ly/4hE1ifz兩展穿梭巴士安排https://www.hktdc.com/event/hkjewellery/tc/travel-to-fairground-hkcechttps://www.hktdc.com/event/hkdgp/tc/travel-to-fairground-awe展會活動https://www.hktdc.com/event/hkjewellery/tc/intelligence-hubhttps://www.hktdc.com/event/hkdgp/tc/intelligence-hub香港貿發局新聞中心:http://mediaroom.hktdc.com/tc傳媒查詢香港貿易發展局傳訊及公共事務部:夏妙婷電話:(852) 2584 4575電郵:sharon.mt.ha@hktdc.org張希汶電話:(852) 2584 4272電郵:serena.hm.cheung@hktdc.org劉茸電話:(852) 2584 4472電郵:clayton.y.lawuw@hktdc.org香港貿易發展局簡介香港貿易發展局(香港貿發局)是於1966年成立的法定機構,負責促進、協助和發展香港貿易。香港貿發局在世界各地設有超過50個辦事處,其中13個設於中國內地,致力推廣本港作為雙向環球投資及商業樞紐。 香港貿發局通過舉辦國際展覽會、會議及商貿考察團,為企業(尤其是中小企)開拓內地和環球市場的機遇。香港貿發局亦通過研究報告和數碼資訊平台,提供最新的市場分析和產品資訊。有關香港貿發局的其他資訊,請瀏覽www.hktdc.com/aboutus/tc。 Copyright 2025 亞太商訊 via SeaPRwire.com.

The 17th Annual Global CSR & ESG Summit 2025 Concludes in Ho Chi Minh City, Setting New Standards in Sustainability

HO CHI MINH CITY, VIETNAM, Feb 27, 2025 - (ACN Newswire via SeaPRwire.com) - The 17th Annual Global CSR & ESG Summit 2025, themed "Scaling Impact and Redefining Value in Sustainability," came to a successful close yesterday at the Mai House Saigon Hotel. The event marked a significant milestone in the field of corporate social responsibility (CSR) and environmental, social, and governance (ESG) initiatives, attracting over 200 experts, practitioners, NGO representatives, and media partners.Hosted by The Pinnacle Group International in collaboration with the Sustainable Technology Centre, this year’s summit assembled industry leaders, policymakers, and subject matter experts to explore innovative ESG strategies and solutions to creating value for organisations and the community at large.  The event showcased insightful discussions, on pressing issues including climate action, transition finance, carbon emissions, diversity and inclusion, ethical governance, and community engagement."Green Man" Matthias Gelber captivates the audience at The 17th Annual Global CSR & ESG Summit and Awards 2025 with his passionate keynote, urging businesses to embrace sustainable practices.Industry Leaders Convene to Drive Sustainability and ESG InnovationThe summit brought together top industry leaders and experts to explore solutions for achieving net-zero goals and advancing ESG initiatives. Mr. Mai Lam Dong, Cluster President of Schneider Electric Vietnam & Cambodia, emphasized the urgent need for carbon reduction technologies to achieve a sustainable future. He highlighted the role of smart grids, AI-driven energy management, and automation in enhancing efficiency and reducing emissions. By integrating renewables, microgrids, and electrification, businesses can accelerate the transition to a low-carbon economy. With Vietnam’s net-zero commitments, he called for stronger collaboration between industry, policymakers, and technology providers to scale these solutions for lasting environmental and economic impact.Building on this, Huang Yi Chun, Regional Leader for Climate Action & Sustainability at Gensler, shared how digital design is reshaping the built environment. He discussed AI-driven simulations and parametric design, suggesting ideas for businesses to integrate sustainability into urban planning and architecture to meet evolving regulatory demands.Prof. Dr. Geoffrey Williams, a leading economist and government advisor moderated a panel consisting of leaders from Bridgestone Asia Pacific, PT Hengjaya Mineralindo, and PT TBS Energi Utama where they shared insights on embedding ESG into workforce development, responsible resource management, and financing sustainable growth.Highlighting technology’s role in ESG transparency, Susanna Hasenoehrl, Head of Sustainability at SAP Asia, demonstrated how AI, big data, and blockchain are transforming sustainability reporting and corporate accountability in enabling faster and more accurate results.In another panel where strategic partnerships in sustainability were explored, Dr. Doseba Sinay of World Vision highlighted the transformative power of collaboration in addressing social and environmental challenges, emphasizing the need for multi-stakeholder engagement to create lasting impact. He shared how World Vision’s initiatives—ranging from reforestation and clean water access to livelihood programs—have been strengthened through corporate and government partnerships. Speakers from HEINEKEN Vietnam, Sarawak Energy Berhad, and Evermos echoed this sentiment, discussing how businesses can integrate ESG principles into their operations through sustainable supply chains, circular economy models, and community-driven projects. The discussion reinforced that cross-sector collaboration is not just beneficial but essential for scaling meaningful and measurable sustainability outcomes.The summit concluded with an inspiring keynote by Prof. Dr. Richard David Hames, urging businesses to remain committed to CSR and ESG as key drivers of long-term value. The event culminated in an awards ceremony recognizing outstanding contributions, with Guest of Honour Mr Vu Minh Ly, Vice Director of Resource and Environment Communication Centre, Ministry of Natural Resources and Environment and Dr Tran Quy, President of Vietnam Institute of Digital Economy Development.The Global CSR & ESG Summit 2025 concluded with a renewed commitment from industry leaders to scaling ESG initiatives and corporate social responsibility (CSR) practices that drive both environmental impact and business value. Delegates engaged in insightful discussions on integrating sustainability into corporate strategies, leveraging technology for ESG transparency, and forging partnerships to create long-term economic and social benefits. The summit provided actionable strategies for businesses to align profitability with purpose, ensuring that sustainability remains at the core of corporate decision-making.On the second day, delegates explored the Mekong Delta, gaining firsthand insights into the intersection of sustainable tourism, local economic empowerment, and environmental preservation. The tour included a scenic cruise along the Mekong River, visits to traditional riverside villages and coconut processing workshops, and a sampan ride through the region’s lush waterways. Delegates also experienced the cultural heritage of the Delta through local folk music, seasonal delicacies, and an authentic riverside meal, reinforcing the importance of preserving both ecological and cultural landscapes in sustainability efforts.Celebrating success! Recipients proudly display their awards at the 17th Annual Global CSR & ESG Summit and Awards 2025, recognizing their outstanding contributions to corporate social responsibility and environmental sustainability.Results for Global CSR & ESG Awards 2025Award Categories for 2025:Best Environmental Excellence AwardBest Community Programme AwardExcellence in Provision of Literacy & Education AwardEmpowerment of Women AwardBest Workplace PracticesCSR & ESG Leadership AwardBest CEOBest CFOBest Corporate Communications & Investors Relations TeamAdditionally, awards were given to companies excelling in their respective regions, including awards for Best in Thailand, Indonesia, Cambodia, Vietnam, Malaysia, and India.Best CEO         Up to USD 500 Million in Market CapitalizationGold: BHG Retail REITPlatinum: Thanh Thanh Cong Bien Hoa Joint Stock CompanyUSD 1 Billion and above in Market CapitalizationPlatinum: Pertamina International ShippingBest CFO         USD 1 Billion And Above in Market CapitalizationPlatinum: Pertamina International ShippingBest Corporate Communications & Investor Relations Team AwardUp to USD 500 Million Market CapitalizationSilver: BHG Retail REITGold: PT TBS Energi Utama Tbk (TBS)Platinum: Thanh Thanh Cong Bien Hoa Joint Stock CompanyUSD 1 Billion and above in Market CapitalizationPlatinum: Pertamina International ShippingBest Environmental Excellence AwardUp to USD 500 Million Market CapitalizationBronze: Hirdaramani Vietnam - Fashion Garments LimitedSilver: PT Pertamina EP Bunyu FieldGold: PT. Pertamina Patra Niaga AFT SepingganBank RakyatPlatinum: PT Pertamina EP Sangasanga FieldUSD 500 Million To USD 1 Billion Market CapitalizationSilver: PT Kalimantan Prima PersadaGold: PT Pertamina Patra Niaga AFT JuandaPlatinum: PT Pertamina EP Donggi Matindok FieldUSD 1 Billion And Above in Market CapitalizationBronze: PT Pertamina Patra Niaga Integrated Terminal SurabayaSilver: PT Pertamina Hulu MahakamPertamina International ShippingGold:Pertamina EP Zona 7PT Chandra Asri PacificThai Union GroupPTTEP IndonesiaPlatinum: Bridgestone Asia PacificBest Community Programme AwardUp to USD 500 Million Market CapitalizationBronze: PT Pertamina Hulu Sanga SangaSilver:EvermosHirdaramani Vietnam - Fashion Garments LimitedNagaWorld LimitedHengjaya MineralindoThanh Thanh Cong Bien Hoa Joint Stock CompanyGold:PT Pertamina EP Asset 4 Sukowati FieldPT Badak NGLPT Pertamina Patra Niaga FT MaosPertamina Patra Niaga Fuel Terminal RewuluPT Pertamina Patra Niaga Integrated Terminal SemarangPlatinum: PT Pertamina Patra Niaga Fuel Terminal TubanUSD 500 Million To USD 1 Billion Market CapitalizationBronze:Amazon Web ServicesPT Suprabari Mapanindo MineralSilver:PT Asmin Bara BronangPT Pertamina Patra Niaga Fuel Terminal SanggaranGold:Samsung VietnamAkzo Nobel VietnamPT Kalimantan Prima PersadaPlatinum: PT Pertamina Patra Niaga Fuel Terminal Tanjung GeremUSD 1 Billion And Above in Market CapitalizationBronze:Pertamina EP Papua FieldPT Pamapersada NusantaraPT Pertamina EP Donggi Matindok FieldPT Pertamina EP Sukowati FieldPT Pertamina Geothermal Energy Tbk Area UlubeluSilver:Bumi ResoucesPertamina EP Zona 7PT Chandra Asri PacificJOB Pertamina-Medco E&P Tomori SulawesiPertamina International ShippingGold:PT Pertamina Patra Niaga Integrated Terminal BanjarmasinSarawak Energy BerhadPT Pertamina Patra Niaga Fuel Terminal TarakanPT Pertamina Patra Niaga AFT SupadioCentral RetailPT Pertamina Patra Niaga Integrated Terminal PontianakPT Pertamina Patra Niaga Aviation Fuel Terminal BILPlatinum: Vinmec Healthcare SystemExcellence In Provisional Of Literacy & Education AwardLess Than USD 500 Million Market CapitalizationPlatinum: PT SAPTAINDRA SEJATI USD 500 Million To USD 1 Billion Market CapitalizationSilver: Amazon Web ServicesGold: PT Kalimantan Prima PersadaPlatinum: Samsung VietnamUSD 1 Billion And Above in Market CapitalizationGold: Pertamina International ShippingPlatinum: Sarawak Energy BerhadEmpowerment Of Women AwardUp to USD 500 Million Market CapitalizationSilver: DiageoGold: PT PLN Nusantara Power UP Gresik Platinum: Thanh Thanh Cong Bien Hoa Joint Stock CompanyUSD 500 Million to USD 1 Billion in Market CapitalizationGold: Pertamina International ShippingPlatinum: PT Kalimantan Prima PersadaUSD 1 Billion And Above in Market CapitalizationBronze: Bumi ResoucesSilver: Pertamina EP Zona 7Gold: PT Pertamina Hulu MahakamPlatinum: Sarawak Energy BerhadBest Workplace Practises         Up to USD 500 Million Market CapitalizationPlatinum: Thanh Thanh Cong Bien Hoa Joint Stock CompanyUSD 1 Billion And Above in Market CapitalizationPlatinum: Vinmec Healthcare SystemProduct Excellence Award       Up to USD 500 Million in Market CapitalizationPlatinum: CoMem Natural Cosmeceutics Join Stock CompanyUSD 1 Billion and above in Market CapitalizationPlatinum: Pertamina International ShippingCSR & ESG Leadership Award   Up to USD 500 Million Market CapitalizationBronze: DiageoSilver: Asia Society for Social Improvement and Sustainable TransformationBHG Retail REIT      Gold: CoMem Natural Cosmeceutics Join Stock CompanyHirdaramani Vietnam - Fashion Garments LimitedPlatinum: Thanh Thanh Cong Bien Hoa Joint Stock CompanyUSD 500 Million To USD 1 Billion Market CapitalizationPlatinum: Samsung VietnamUSD 1 Billion And Above in Market CapitalizationBronze: PT Indocement Tunggal Prakarsa TbkSilver: PT Chandra Asri PacificGold: Home Credit Vietnam Financial Company LimitedPlatinum: Advanta Enterprises Limited (AEL)Best Country Excellence – Best in CambodiaUSD 1 Billion And Above in Market CapitalizationPlatinum: NagaWorld LimitedBest Country Excellence – Best in ThailandUSD 1 Billion And Above in Market CapitalizationPlatinum: Thai Union GroupBest Country Excellence – Best In IndonesiaUp to USD 500 Million Market CapitalizationGold: PT PLN Indonesia Power UBP SuralayaPlatinum: PT Pertamina Geothermal Energy Tbk Area LahendongUSD 500 Million To USD 1 Billion Market CapitalizationPlatinum: PT Pertamina Hulu Energi West MaduraUSD 1 Billion And Above in Market CapitalizationGold: PT Kilang Pertamina Internasional Refinery Unit III PlajuPlatinum: PT Kalimantan Prima PersadaBest Country Excellence – Best in VietnamUp to USD 500 Million Market CapitalizationPlatinum: Thanh Thanh Cong Bien Hoa Joint Stock CompanyUSD 1 Billion And Above in Market CapitalizationPlatinum: Vinmec Healthcare SystemBest Country Excellence – Best in MalaysiaUp to USD 500 Million Market CapitalizationPlatinum: Tata Consultancy ServicesUSD 1 Billion And Above in Market CapitalizationPlatinum: Sarawak Energy BerhadBest Country Excellence – Best in IndiaUp to USD 500 Million Market CapitalizationPlatinum: Bridgestone Asia PacificFor media inquiries, please contact:Eric Khoo (Mr.)Head of Global Events and PartnershipsThe Pinnacle Group InternationalEmail: eric.khoo@pinnaclegroup.globalTel: +65 8383 2480 Copyright 2025 ACN Newswire via SeaPRwire.com.

MHI-MS Completes Domestic Development of Vehicle Transport Robot

Smaller "head" than the existing model, more efficient for handling subcompact mini vehicles・Domestic production allows for more focused after-sales service, as well as customization in a timely manner to meet customer needsTOKYO, Mar 4, 2025 - (JCN Newswire via SeaPRwire.com) - Mitsubishi Heavy Industries Machinery Systems (MHI-MS), a part of Mitsubishi Heavy Industries (MHI) Group, has finalized domestic development of an autonomous car and vehicle transportation and storage system (hereafter referred to as "a vehicle transport robot") to move automobiles autonomously, and has started trial operations and endurance tests at its production plant.MHI-MS launched a collaborative project in 2021 with its partner Stanley Robotics (SR), a French venture firm, with the intention of importing the robots from France and marketing them domestically. It was later decided to produce a domestic model with Japanese specifications, allowing for more focused after-sales service in Japan, as well as customization in a timely manner to meet customer needs. With the switch to a domestic production policy, MHI-MS is pursuing measures for domestic production, including submitting applications and registering core patents in Japan.(Note1) The Japan market model has a smaller "head" than the existing model, this makes smaller vehicles easier to handle. In addition, at the customer's request, MHI-MS provides a "dress-up service" where the exterior of the head can be customized based on the customer's preference.MHI-MS has established a network of about 100 maintenance and other service bases in Japan. This hub network can also be used to provide service for vehicle transport robots. The adoption of domestic production will allow MHI-MS to provide "Made in Japan" quality with prompt after-sales service.Utilizing these robots for automated transport of finished vehicles(Note2) will greatly improve the work environment for workers engaged in vehicle transport on a regular basis, even in bad weather, extreme heat, and other harsh environments, while also responding to the demands of the logistics industry such as DX (digital transformation) and efficiency improvement.For automated valet parking(Note3) at commercial facilities, the robot will park the car in a vacant space, making it possible to turn the distant parking spaces that people tend to avoid into "close" parking spaces. It also eliminates the problem of drivers being distracted while looking for a vacant space, and causing an accident due to inattention. Further, CO2 emissions from driving vehicles through the site are suppressed, contributing to the realization of a society that is friendly to both people and the planet.Going forward, MHI-MS, as a pioneer in vehicle transport robots in Japan, will combine this innovative technology with the advanced intelligent transportation systems including traffic flow control technology, unmanned system monitoring and EV operation management technology developed by MHI Group to provide services that meet a wide range of customer needs.(1) See the following press release regarding the domestic registration of core patents. www.mhi.com/jp/news/24091101.html (Japanese)(2) The system can operate 24 hours a day year-round in automobile factories, ports, motor pools, and other compounds where vehicles need to be moved, solving the problem of a shortage of skilled drivers while at the same time delivering safe transport at low cost.(3) When the driver stops at a designated berth close to the facility, instead of having to find a parking space on their own, the vehicle transport robot moves the vehicle to a vacant space, taking over parking on behalf of the driver. The process is reversed when retrieving the vehicle, with the robot transporting the vehicle back to the berth at the time specified by the driver in advance using the smartphone app. For drivers, there is no need to find a parking space or park, and no concerns about brushing against the adjacent car when opening the door. For more information on the demonstration test of automated valet parking conducted at a commercial facility in Japan, see the following press releases. www.mhi.com/news/220613.htmlhttps://www.mhi.com/news/221118.htmlAbout MHI GroupMitsubishi Heavy Industries (MHI) Group is one of the world’s leading industrial groups, spanning energy, smart infrastructure, industrial machinery, aerospace and defense. MHI Group combines cutting-edge technology with deep experience to deliver innovative, integrated solutions that help to realize a carbon neutral world, improve the quality of life and ensure a safer world. For more information, please visit www.mhi.com or follow our insights and stories on spectra.mhi.com. Copyright 2025 JCN Newswire via SeaPRwire.com.

Eisai Receives Regulatory Review Outcome for Lecanemab as a Treatment for Early Alzheimer’s Disease in Australia

TOKYO and CAMBRIDGE, Mass., Mar 4, 2025 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. and Biogen Inc. announced today that the Therapeutic Goods Administration (TGA) of Australia has confirmed the initial decision to decline the approval of humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody lecanemab (generic name) as a treatment for early Alzheimer’s disease (AD) (mild cognitive impairment due to AD and mild AD dementia).In October 2024, the TGA made the decision not to register lecanemab in Australia for the treatment of patients with early AD. In December 2024, Eisai requested reconsideration of the decision, proposing to the TGA the same apolipoprotein E4 (ApoE4) noncarrier and heterozygote indication that was agreed by the Medicines and Healthcare products Regulatory Agency (MHRA) and European Medicines Agency (EMA). In the course of the reconsideration of the initial decision, the TGA proposed an alternative narrow therapeutic indication only for ApoE4 noncarriers as an increasing number of ApoE4 alleles is a potential risk factor for ARIA. They did not agree that safety has been established for ApoE4 heterozygotes. Eisai proposed alternative indications, one of which was to maintain the ApoE4 noncarrier and heterozygote indication, but with heterozygotes treated in specialist centers and supervised by physicians with expertise in treatment of AD and monitoring for ARIA; however, the TGA rejected our proposal. “We are extremely disappointed and surprised by the TGA’s decision and understand that the AD community in Australia may also feel disheartened, especially given that eleven countries and regions across the globe have granted marketing authorization. We tried earnestly to reach a compromise with the TGA on an indication that would adequately represent the data in the application but were unfortunately unsuccessful at this time,” said Lynn Kramer, M.D., Chief Clinical Officer at Eisai. “The TGA proposed a narrow indication that would limit access to only ApoE4 noncarriers. This indication would deny approximately two-thirds (~70%) of all potentially eligible patients access to a treatment that could slow the progression of AD. Eisai believes ApoE4 heterozygote carriers should at least also have access to lecanemab given the similar benefit-risk profile to the noncarrier population. Therefore, we could not accept this restrictive indication as it is not patient-centric. Given this outcome, we are deeply concerned that Australians living with Alzheimer’s disease will not have access to a treatment that slows the progression of early Alzheimer’s disease by targeting its underlying causes. Eisai remains committed to ensuring eligible Australians with early Alzheimer’s disease can access lecanemab and is exploring options to achieve this, including potentially seeking review by the Administrative Review Tribunal.”In Australia, the number of people living with dementia was estimated to be approximately 411,000 in 2023, and is reported to increase to approximately 849,000 by 2058.1 AD is considered the most common cause of dementia, typically accounting for 60-70% of cases.2 AD progresses over time in stages with increasingly severe symptoms that greatly impact not only those who are living with AD, but also their loved ones, care partners and society. There is a significant unmet need for new treatment options that slow down the progression of AD from its early stage.=Aβ which is involved in the onset of AD, gradually aggregates in the brain 15 to 20 years before symptoms appear, eventually forming insoluble plaques, a pathological feature of AD. AD is a progressive, relentless disease caused by a continuous underlying neurotoxic process that begins before and continues after plaque removal.3,4,5 Only lecanemab works to fight AD in two ways: continuously clearing protofibrils* ,the most toxic Aβ species, and rapidly clearing plaque. This mechanism has been shown to reduce the rate of disease progression and to slow cognitive and functional decline. Lecanemab has been approved in the U.S., Japan, China, South Korea, Hong Kong, Israel, the United Arab Emirates, the United Kingdom, Mexico, Macau and Oman. Regulatory filings for the treatment have been made in the EU and 17 other countries and regions. In the EU, in February 2025, the Committee for Medicinal Products for Human Use reaffirmed its positive opinion for lecanemab in early AD, adopted in November 2024, and the European Commission is proceeding with the decision-making process for lecanemab’s marketing authorization.Eisai serves as the lead for lecanemab’s development and regulatory submissions globally with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority.*Protofibrils are believed to contribute to the brain injury that occurs with AD and are considered to be the most toxic form of Aβ, having a primary role in the cognitive decline associated with this progressive, debilitating condition.6Protofibrils cause injury to neurons in the brain, which in turn, can negatively impact cognitive function via multiple mechanisms, not only increasing the development of insoluble Aβ plaques but also increasing direct damage to brain cell membranes and the connections that transmit signals between nerve cells or nerve cells and other cells. It is believed the reduction of protofibrils may prevent the progression of AD by reducing damage to neurons in the brain and cognitive dysfunction.7About lecanemabLecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ).Lecanemab is approved in the U.S.,8 Japan,9 China,10 South Korea,11 Hong Kong,12 Israel,13 the United Arab Emirates,14the United Kingdom,15 Mexico16, Macau and Oman. Eisai has submitted applications for approval of lecanemab in 17 countries and regions. In the EU, in February 2025, the Committee for Medicinal Products for Human Use reaffirmed its positive opinion for lecanemab in early AD, adopted in November 2024, and the European Commission is proceeding with the decision-making process for lecanemab’s marketing authorization. In January 2025, the supplemental Biologics License Application (sBLA) for intravenous (IV) maintenance dosing of the treatment was approved in the U.S. After an 18 months initiation phase with once every two weeks of dosing, a transition to the maintenance dosing regimen of 10 mg/kg once every four weeks or continuing 10 mg/kg once every two weeks may be considered. Additionally, the U.S. Food and Drug Administration (FDA) accepted Eisai’s Supplemental Biologics License (BLA) for the LEQEMBI subcutaneous autoinjector for weekly maintenance dosing in January 2025 and set a PDUFA action date for August 31, 2025.Since July 2020 the Phase 3 clinical study (AHEAD 3-45) for individuals with preclinical AD, meaning they are clinically normal and have intermediate or elevated levels of amyloid in their brains, is ongoing. AHEAD 3-45 is conducted as a public-private partnership between the Alzheimer's Clinical Trial Consortium that provides the infrastructure for academic clinical trials in AD and related dementias in the U.S, funded by the National Institute on Aging, part of the National Institutes of Health, Eisai and Biogen. Since January 2022, the Tau NexGen clinical study for Dominantly Inherited AD (DIAD), that is conducted by Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, is ongoing and includes lecanemab as the backbone anti-amyloid therapy.About the Collaboration between Eisai and Biogen for ADEisai and Biogen have been collaborating on the joint development and commercialization of AD treatments since 2014. Eisai serves as the lead of lecanemab development and regulatory submissions globally with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority.About the Collaboration between Eisai and BioArctic for ADSince 2005, Eisai and BioArctic have had a long-term collaboration regarding the development and commercialization of AD treatments. Eisai obtained the global rights to study, develop, manufacture and market lecanemab for the treatment of AD pursuant to an agreement with BioArctic in December 2007. The development and commercialization agreement on the antibody lecanemab back-up was signed in May 2015.About Eisai Co., Ltd.Eisai's Corporate Concept is "to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides." Under this Concept (also known as human health care (hhc) Concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology.In addition, we demonstrate our commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), by working on various activities together with global partners.For more information about Eisai, please visit www.eisai.com (for global headquarters: Eisai. Co., Ltd.), us.eisai.com (for U.S. headquarters: Eisai, Inc.) or www.eisai.eu (for Europe, Middle East, Africa, Russia, Australia and New Zealand headquarters: Eisai Europe Ltd.), and connect with us on X (global and U.S), LinkedIn (for global, U.S.and EMEA) and Facebook (global).About BiogenFounded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients’ lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth.The company routinely posts information that may be important to investors on its website at www.biogen.com. Follow Biogen on social media – Facebook, LinkedIn, X, YouTube Biogen Safe HarborThis news release contains forward-looking statements, including about the potential clinical effects of lecanemab; the potential benefits, safety and efficacy of lecanemab; potential regulatory discussions, submissions and approvals and the timing thereof; the treatment of Alzheimer's disease; the anticipated benefits and potential of Biogen's collaboration arrangements with Eisai; the potential of Biogen's commercial business and pipeline programs, including  lecanemab; and risks and uncertainties associated with drug development and commercialization. These forward-looking statements may be accompanied by such words as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “goal,” “guidance,” “hope,” “intend,” “may,” “objective,” “plan,” “possible,” “potential,” “predict,” “project,” “prospect,” “should,” “target,” “will,” “would,” and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements. Given their forward-looking nature, these statements involve substantial risks and uncertainties that may be based on inaccurate assumptions and could cause actual results to differ materially from those reflected in such statements.  These forward-looking statements are based on management's current beliefs and assumptions and on information currently available to management. Given their nature, we cannot assure that any outcome expressed in these forward-looking statements will be realized in whole or in part. We caution that these statements are subject to risks and uncertainties, many of which are outside of our control and could cause future events or results to be materially different from those stated or implied in this document, including, among others, uncertainty of long-term success in developing, licensing, or acquiring other product candidates or additional indications for existing products; expectations, plans and prospects relating to product approvals, approvals of additional indications for our existing products, sales, pricing, growth, reimbursement and launch of our marketed and pipeline products; our ability to effectively implement our corporate strategy; the successful execution of our strategic and growth initiatives, including acquisitions; the risk that positive results in a clinical trial may not be replicated in subsequent or confirmatory trials or success in early stage clinical trials may not be predictive of results in later stage or large scale clinical trials or trials in other potential indications; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; the occurrence of adverse safety events, restrictions on use with our products, or product liability claims; and any other risks and uncertainties that are described in other reports we have filed with the U.S. Securities and Exchange Commission.  These statements speak only as of the date of this press release and are based on information and estimates available to us at this time. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. Investors are cautioned not to put undue reliance on forward-looking statements. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and in our subsequent reports on Form 10-Q and Form 10-K, in each case including in the sections thereof captioned “Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in our subsequent reports on Form 8-K. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements whether as a result of any new information, future events, changed circumstances or otherwise.References(1) Dementia in Australia https://www.aihw.gov.au/reports/dementia/dementia-in-aus/contents/population-health-impacts-of-dementia/prevalence-of-dementia(New Window)(2) World Health Organization. Dementia Fact Sheet. March 2023. Available at: https://www.who.int/news-room/fact-sheets/detail/dementia(New Window).(3) Eisai presents full results of lecanemab Phase 3 confirmatory Clarity AD study for early Alzheimer's disease at Clinical Trials on Alzheimer's Disease (CTAD) conference. Available at: https://www.eisai.co.jp/news/2022/news202285.html(New Window)(4) van Dyck, H., et al. Lecanemab in Early Alzheimer’s Disease. New England Journal of Medicine. 2023;388:9-21. https://www.nejm.org/doi/full/10.1056/NEJMoa2212948(New Window).(5) Hampel H, Hardy J, Blennow K, et al. The amyloid-β pathway in Alzheimer’s disease. Mol Psychiatry. 2021;26(10):5481-5503.(6) Amin L, Harris DA. Aβ receptors specifically recognize molecular features displayed by fibril ends and neurotoxic oligomers. Nat Commun. 2021;12:3451. doi:10.1038/s41467-021-23507-z(7) Ono K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706.(8) U.S. Food and Drug Administration. 2023. FDA Converts Novel Alzheimer's Disease Treatment to Traditional Approval. Last accessed: October 2024.(9) Reuters. 2023. Japan approves Alzheimer's treatment Leqembi by Eisai and Biogen. Last accessed: October 2024.(10) The Pharma Letter. 2024. Brief - Alzheimer drug Leqembi now approved in China. Last accessed: October 2024.(11) Pharmaceutical Technology. 2024. South Korea's MFDS approves Eisai-Biogen's LEQEMBI for Alzheimer's. Last accessed: October 2024.(12) Pharmaceutical Technology. 2024. Hong Kong approves Leqembi for Alzheimer's treatment. Last accessed: October 2024.(13) BioSpace. 2024. Leqembi approved for the treatment of Alzheimer's disease in Israel. Last accessed: October 2024.(14) United Arab Emirates Ministry of Health & Prevention. 2024. Registered Medical Product Directory. Leqembi. Last accessed: October 2024.(15) BioSpace. 2024. Leqembi authorized for early Alzheimer's disease in Great Britain. Last accessed: October 2024.(16) COFEPRIS authorizes innovative treatment for Alzheimer’s patients. Available at: https://bit.ly/3OKks6Y(New Window). Last accessed: December 2024.MEDIA CONTACTSEisaiEisai Co., Ltd.Public Relations DepartmentTEL: +81 (0)3-3817-5120Eisai Europe, Ltd.(UK, Europe, Australia, New Zealand and Russia)EMEA Communications Department+44 (0) 797 487 9419Emea-comms@eisai.netEisai Inc. (U.S.)Libby Holman+1-201-753-1945Libby_Holman@eisai.comEisai Co., Ltd.Public Relations DepartmentTEL: +81 (0)3-3817-5120Eisai Europe, Ltd.(UK, Europe, Australia, New Zealand and Russia)EMEA Communications Department+44 (0) 797 487 9419Emea-comms@eisai.netEisai Inc. (U.S.)Libby Holman+1-201-753-1945Libby_Holman@eisai.comBiogen Inc.Jack Cox+ 1-781-464-3260public.affairs@biogen.com Copyright 2025 JCN Newswire via SeaPRwire.com.

Prideone Entertainment announces concept for post-war film to mark 80th anniversary of the end of World War II

TOKYO, March 4, 2025 - (JCN Newswire via SeaPRwire.com) - Prideone Entertainment Co., Ltd. (Headquarters: Shibuya, Tokyo; CEO: Yasushi Akutagawa) has announced the concept for a new film tentatively titled "Fellers" to mark the 80th anniversary of the post-war era.Akutagawa said, "Fellers is an epic historical spectacle that looks behind the scenes of history from the perspective that it was an American officer, Bonner Fellers, and a group of Christians who saved the Emperor immediately after World War II."Akutagawa, who was the original planner and producer of the 2012 American-Japanese film Emperor (with a production budget of 3 billion yen), also focused on Bonner Fellers in that film. However, various interpretations were incorporated, and the final cut differed considerably from the original idea. The film became a love story between Bonner Fellers, played by Matthew Fox, and an imaginary Japanese lover.In response, various individuals, including Yoshiko Isshiki, former chairperson of Keisen Women's School, strongly suggested that a true-to-history depiction of Fellers be made in this 80th year since the end of the war. This led Akutagawa to create a new film from the fresh perspective. A Japanese director has been chosen for the project, and an original script based on historical facts has already been completed.Post-war Japan began on August 30, 1945, when General Douglas MacArthur, the Supreme Commander of the Allied Powers, landed in Japan and started the full-scale American occupation. MacArthur initiated mass arrests of war criminals and began activities to prosecute them. In the United States, there were strong calls from both the government and public to prosecute the Emperor. On the other hand, MacArthur considered the construction of an "anti-communist bulwark" in the Far East to be of utmost importance. He also eyed a future political career and a potential presidential run, so he felt that he needed to achieve success in post-war governance of Japan at all costs. From this viewpoint, he believed that arresting and executing the Emperor would gain him popular support. MacArthur ordered his subordinates to gather evidence that the Emperor had played a decisive role in Japan’s decision to go to war, including the attack on Pearl Harbor. Meanwhile, Bonner Fellers, an American officer with a deep knowledge of Japan, was tasked by MacArthur to investigate. Fellers, who had become acquainted with Yuri Isshiki before the war, was persuaded by the writings of Lafcadio Hearn, a renowned writer he was introduced to by Yuri, and believed that the Emperor should not be executed. Fellers immediately began searching for the whereabouts of Yuri and her mentor, Michi Kawai. This marked the beginning of a grand political drama and historical spectacle that would lay the foundations for what is now modern Japan. Had these events not unfolded as they did, Japan as we know it might not have existed.Currently, the project is progressing with filming planned for 2027 (in Japan and New Zealand) and release in the fall of 2028. Prideone Entertainment is forecasting a production budget of 4 billion yen, with an additional 1 billion yen for prints and advertising, and is seeking financing options.About the Producer and Executive Producer, Yasushi Akutagawa:Born April 3, 1956, in Kumamoto City, Kumamoto Prefecture. He graduated from the Film Department of the College of Art at Nihon University. Akutagawa started making 8mm films while attending Kumamoto Prefectural Seiseiko High School and decided to pursue a career in film production at university. After graduation, he worked at a major advertising agency before founding Prideone Entertainment Co., Ltd. Since then, he has been involved in producing a wide range of projects in film, television, theater, and radio.Notable Works:- 1991: Futari (Starring: Hikari Ishida) Directed by Nobuhiko Obayashi- 1995: Ashita (Starring: Kaori Takahashi, Yasufumi Hayashi) Directed by Nobuhiko Obayashi- 1998: Kaze no Uta ga Kikitai (Starring: Ryo Amamiya, Yuri Nakae, Tokyo International Film Festival Special Invitation) Directed by Nobuhiko Obayashi- 1999: Ano Natsu no Hi (Starring: Keiju Kobayashi, Yubari International Fantastic Film Festival Special Invitation) Directed by Nobuhiko Obayashi- 2000: Den'en no Ytsu (Starring: Tomokazu Miura, Mitsuko Baisho, Tokyo International Film Festival Special Invitation) Directed by Keisuke Kawahara- 2013: Emperor (Starring: Matthew Fox) Directed by Peter WebberFor inquiries:Prideone Entertainment Co., Ltd.https://yasushi-akutagawa.studio.site/PR: Tsukiokaakidiginfo@gmail.com  Copyright 2025 JCN Newswire via SeaPRwire.com.

赤子城科技發佈盈利預告:2024年收入超50億,調整後經營利潤近10億

EQS 新聞 via SEAPRWire.com / 2025-03-04 / 22:09 UTC+8   赤子城科技發佈盈利預告:2024年收入超50億,調整後經營利潤近10億   [3月4日 – 香港] 領先的全球化社交娛樂公司 – 赤子城科技有限公司(「赤子城科技」或「本公司」,股份代號:9911;連同其附屬公司統稱「本集團」)欣然發佈 2024 年度盈利預告,受惠於 AI 技術推動多樣化社交產品快速發展,公司營收實現爆發增長,利潤亦實現大幅提升。公告顯示,截至 2024 年 12 月 31 日止年度,公司總收入約為人民幣50.0至52.0 億元,較2023年同期增長約51.1%至57.2%;淨利潤約為人民幣 7.7至8.1億元,經調整EBITDA約為人民幣 9.5至9.9億元,同比增長約 40.7%至46.7%。   AI 驅動社交「灌木叢」加速生長   近年來,赤子城科技聚焦泛人群社交業務,通過深入紮根本地和垂類產品創新,形成以 MICO、YoHo、TopTop 和 SUGO 為代表的社交產品“灌木叢”,產品矩陣勢能持續增強。   2024 年,公司泛人群社交業務保持高速增長。在已有產品穩定貢獻收入及利潤的同時,新產品繼續爆發,其中SUGO 全年收入同比增長超 200%,成為公司單月流水規模最高的社交產品,在沙特阿拉伯、土耳其、阿聯酋等多國社交應用收入排行榜中穩居前列;TopTop 也快速發展,全年收入增長超 100%。       同時,AI 技術在業務場景中的應用逐步深入,助力業務從研發、運營到行銷推廣多方面全面提高效益。尤其是公司自主研發的多模態算法模型Boomiix的持續升級,有效提升產品的社交效率及用戶付費意願。以 SUGO 為例,在 Boomiix 的加持下,其年末 ARPU 值較年初提升超 20%,商業化效率顯著優化。   目前赤子城科技的產品「灌木叢」已在全球各市場蓬勃生長,其 AI 佈局的驅動效應也已初步顯現。隨著「社交矩陣+ AI 引擎」的增長模式運行暢順,赤子城科技有望持續放大技術驅動效應,在全球社交賽道挖掘更大的價值。   持續深耕中東北非,加固本地化壁壘   作為最早深入中東北非市場的社交娛樂公司之一,赤子城科技已在該區域深耕近十年,形成深厚的「本地化」壁壘。2024 年,赤子城科技持續挖掘這一戰略市場的增長空間,並在全球市場穩步拓展業務版圖。   根據 Mordor Intelligence 預測,中東媒體和娛樂市場規模將持續增長,預計 2029 年將達到 669.9 億美元。目前,中東市場已成為公司培育爆款產品的沃土,通過積極的市場活動和持續的產品服務升級,公司本地化優勢不斷加深,多款產品在該市場保持增長,穩居當地應用商店榜單前列。   2024 年下半年,赤子城科技正式獲得沙特投資部(MISA)頒發的區域總部許可證(RHQ License),成為最早在沙特成立區域總部的全球化社交娛樂公司之一,將幫助公司進一步加固在中東市場的本地化壁壘。       與此同時,公司亦積極開拓東南亞、日韓、北美等市場,尋找多元增長機遇。其中,多元人群社交業務繼續重點發力海外市場,全球化的多元人群社交平台 HeeSay 在東南亞的優勢地位進一步鞏固。通過豐富社交功能及深化生態運營,HeeSay 不斷提升產品社區屬性,並通過系列線下活動強化用戶對社區的認同感,品牌影響力不斷提升。   精品遊戲開始盈利,進入回收週期   在積極推進核心社交業務戰略佈局的同時,公司對精品遊戲、社交電商等創新業務板塊持續投入,以精品遊戲為代表的「第二增長曲線」正逐步清晰。   其中,由公司獨立研發並交付外部發行的精品遊戲實現流水約7.05 億元人民幣,較 2023 年增長約 80.4%。值得注意的是,2024 年精品遊戲業務第一次為赤子城科技貢獻收入,意味著該業務進入盈利階段。   伴隨著 AI 技術不斷應用在業務全流程中,精品遊戲業務持續突破。其中,旗艦遊戲 Alice's Dream: Merge Games 表現亮眼,自上線以來多次登上知名數據機構發佈的行業榜單,並獲得「年度優秀出海遊戲」等獎項。   近年來,赤子城科技在產品多元化及 AI 技術驅動的戰略下,從「強運營」的商業模式逐步升級,形成「產品+運營+增長」協同發力的高品質、規模化增長模型,實現用戶規模、收入規模和增長品質的全面升級,在全球市場的競爭力顯著提升。今年 2 月,赤子城科技被納入 MSCI 全球小盤股指數,這是去年 9 月被納入富時指數之後,公司近期再度進入全球權威股票指數,其在全球資本市場的影響力也進一步提升。   公司亦以實際行動展現對未來發展的堅定信心,2024 年公司累計回購約 4,300 萬股,合計超 1.4 億港元。未來公司將堅定推進「灌木叢」戰略,增強 AI 賦能,持續用多元化產品覆蓋全球社交娛樂市場更多細分賽道,為更多用戶創造美好情緒價值。     有關赤子城科技 赤子城科技是一家全球化的互聯網公司,2019年在港交所主板上市,股票代碼為09911.HK。 公司以「創造美好的情緒價值」為願景,在社交、遊戲等領域打造了數十款面向全球用戶的APP,包括泛人群社交產品 MICO、YoHo、TopTop、SUGO;多元人群社交產品 HeeSay;精品遊戲產品 Alice's Dream: Merge Games等,累計服務過上百個國家和地區的超過10億全球用戶。 赤子城科技深耕中東北非市場,並積極佈局東南亞、歐美、日韓等地區,致力於成為全球最大的社交娛樂公司。   如欲查詢更多資訊,請聯絡: DLK Advisory  pr@dlkadvisory.com  2025-03-04 此財經新聞稿由EQS Group via SEAPRWire.com轉載。本公告內容由發行人全權負責。瀏覽原文: http://www.todayir.com/tc/index.php